GSK plc 6-K, filed Apr 27, 2022
GSK plc (GSK)
6-K
2022-04-27
For: 2022-04-27
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on April 27, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of April 2022
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
|
Issued:
Wednesday, 27 April 2022, London U.K.
|
|
GSK delivers strong Q1 2022 sales of £9.8 billion, +32% AER,
+32% CER;
Total EPS 35.9p +67% AER, +66% CER and Adjusted EPS 32.8p +43% AER,
+43% CER
|
|
|
||
|
Highlights
|
||
|
|
||
|
Strong sales growth across Biopharma and Consumer
Healthcare
|
||
|
●
|
Biopharma:
£7.1 billion +40% AER, +40% CER;+14% AER, +15% CER excluding
COVID-19 solutions
|
|
|
|
-
|
Specialty
Medicines £3.1 billion +98% AER, +97% CER; HIV +15% AER, +14%
CER; Oncology +15% AER, +15% CER; Immuno-inflammation, respiratory
and other +18% AER, +18% CER; COVID-19 solutions (Xevudy) sales £1.3
billion
|
|
|
-
|
Vaccines
£1.7 billion +36% AER, +36% CER; Shingrix £698 million >100%
AER, >100% CER
|
|
|
-
|
General
Medicines £2.3 billion +2% AER, +3% CER
|
|
●
|
Consumer
Healthcare £2.6 billion +14% AER, +14% CER
|
|
|
●
|
Sales
growth also benefited from favourable comparison to Q1
2021
|
|
|
|
|
|
|
Continued R&D delivery and strengthening of
pipeline
|
||
|
●
|
US FDA
regulatory approvals: Cabenuva treatment of virologically
supressed adolescents living with HIV; Triumeq dispersible single tablet
regimen for treatment of children with HIV
|
|
|
●
|
US FDA
regulatory submission acceptance of daprodustat for anaemia of
chronic kidney disease (PDUFA action date 1 February
2023)
|
|
|
●
|
Benlysta approved in China for adults with active lupus
nephritis
|
|
|
●
|
EU
regulatory submission acceptance for Sanofi-GSK COVID-19 vaccine
(Vidprevtyn) and Canadian
regulatory approval for Medicago-GSK COVID-19 vaccine (Covifenz)
|
|
|
●
|
Proposed
acquisition of Sierra Oncology Inc. strengthens late-stage
specialty pipeline. Momelotinib has potential to address
significant unmet medical need of myelofibrosis patients with
anaemia
|
|
|
●
|
Multiple
pipeline catalysts in next nine months, including phase III data
read outs for the RSV Older Adults and meningitis (MenABCWY)
vaccine candidates, Blenrep, Jemperli and otilimab, and phase IIb
data for bepirovirsen
|
|
|
|
|
|
|
Cost discipline supports delivery of improved operating margin and
Adjusted EPS of 32.8p
|
||
|
●
|
Total
Group operating margin 28.6%. Total EPS 35.9p +67% AER, +66%
CER
|
|
|
●
|
Adjusted
Group operating margin 26.7%. Adjusted EPS 32.8p +43% AER, +43%
CER. This included a contribution to growth from COVID-19 solutions
of approximately +15% AER, +15% CER for Q1 2022
|
|
|
●
|
Q1 2022
cash generated from operations £2.8 billion. Q1 2022 free cash
flow £1.7 billion
|
|
|
|
|
|
|
On track to demerge and list Haleon, a new global leader in
consumer healthcare, in July 2022
|
||
|
●
|
New
growth outlooks set out in Q1 2022, for annual organic revenue
growth of 4-6% and sustainable moderate expansion of adjusted
operating margin over medium term at CER
|
|
|
|
|
|
|
Reconfirming 2022 guidance
|
||
|
●
|
GSK
expected to deliver growth in 2022 sales of between 5% to 7% at CER
and growth in 2022 Adjusted operating profit of between 12% to 14%
at CER
|
|
|
●
|
2022
guidance excludes any contribution from COVID-19
solutions
|
|
|
●
|
Dividend
of 14p declared for Q1 2022
|
|
|
|
||
|
Emma Walmsley, Chief Executive Officer, GSK:
“We
have delivered strong first quarter results in this landmark year
for GSK, as we separate Consumer Healthcare and start a new period
of sustained growth. Our results reflect further good momentum
across specialty medicines and vaccines, including the return to
strong sales growth for Shingrix and continuing pipeline
progress. We also continue to see very good momentum in Consumer
Healthcare, demonstrating strong potential of this business ahead
of its proposed demerger in July, to become
Haleon.”
|
|
The Total results are presented in summary on page 2 and under
‘Financial performance’ on page 7 and Adjusted results
reconciliations are presented on page 15. Adjusted results are a
non-IFRS measure that may be considered in addition to, but not as
a substitute for, or superior to, information presented in
accordance with IFRS. Adjusted results are defined on page 20 and
£% or AER% growth, CER% growth, free cash flow and other
non-IFRS measures are defined on page 42. GSK provides guidance on
an Adjusted results basis only, for the reasons set out on page 20.
All expectations, guidance and targets regarding future performance
and dividend payments should be read together with ‘Guidance,
assumptions and cautionary statements’ on page
43.
|
|
Q1 2022 results
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Q1 2022
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
|
|
|
|
9,780
|
|
32
|
|
32
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
|
|
|
|
2,801
|
|
65
|
|
65
|
|
Total
earnings per share
|
|
|
|
|
35.9p
|
|
67
|
|
66
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
|
|
|
|
2,613
|
|
39
|
|
39
|
|
Adjusted
earnings per share
|
|
|
|
|
32.8p
|
|
43
|
|
43
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
generated from operations
|
|
|
|
2,755
|
|
>100
|
|
|
|
|
Free
cash flow
|
|
|
|
|
1,650
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2022 guidance
|
|
We reconfirm our guidance for new GSK in 2022, as set out below.
This guidance is provided at CER and excludes the commercial
benefit of COVID-19 solutions.
In 2022, we expect to continue to deliver on our strategic
priorities. We plan to increase targeted investment in R&D, to
build on and invest behind our top-line momentum for key growth
drivers and to deliver the demerger of our Consumer Healthcare
business in July 2022. Assuming global economies and healthcare
systems approach normality as the year progresses, we expect sales
of Specialty Medicines to grow approximately 10% CER and sales of
General Medicines to show a slight decrease, primarily reflecting
increased genericisation of established Respiratory medicines.
Vaccines sales are expected to grow at a low-teens percentage at
CER for the year. However, as noted at the time of announcing
full-year 2021 results, we anticipated governments’
prioritisation of COVID-19 vaccination programmes and ongoing
measures to contain the pandemic would result in some continued
disruption to adult immunisations. In the first-quarter 2022
Shingrix
demonstrated strong demand recovery,
particularly in the US, as well as channel inventory build and the
benefit of a favourable comparator to Q1 2021. Despite the
potential for short-term pandemic disruption, we continue to expect
strong double-digit growth and record annual sales for
Shingrix
in 2022 based on strong demand in
existing markets and continued geographical
expansion.
Reflecting these factors and our first-quarter 2022 results, we
reconfirm our full-year 2022 guidance for new GSK of sales growth
between 5% to 7% CER and Adjusted operating profit growth between
12% to 14% CER compared to 2021. The guidance includes the future
benefit in royalty income from the settlement and license agreement
with Gilead Sciences, Inc. (Gilead) announced on 1 February
2022.
Medium
term outlooks were provided for Consumer Healthcare at a Capital
Markets Day on 28 February 2022. Until such time as the
formal criteria for treating Consumer Healthcare as a
‘Discontinued operation’ have been satisfied (currently
expected in Q2 2022), GSK will continue to present the Consumer
Healthcare business within ‘Continuing operations’ and
will consolidate the business for reporting purposes until the
demerger has completed.
Dividend
policies and expected pay-out ratios are unchanged for new GSK and
new Consumer Healthcare (subject to new Consumer Healthcare board
approval). The future dividend policies and guidance in relation to
the expected dividend pay-out in 2022 across both new GSK and new
Consumer Healthcare are provided on page 19.
2022 COVID-19 solutions expectations
In 2022, based on known binding agreements with governments, we
expect that COVID-19 solutions will contribute a similar sales
level to 2021, but at a substantially reduced profit contribution
due to the increased proportion of lower margin Xevudy sales. We expect this to reduce the new GSK
Adjusted Operating profit growth (including COVID-19 solutions in
both years) by between 5% to 7%. The overwhelming majority of
expected COVID-19 solutions sales were achieved in the first
quarter this year. In April 2022, the US FDA updated
Xevudy’s authorisation to reflect the increase in
COVID-19 cases caused by the Omicron BA.2 sub-variant and as a
result, Xevudy is no longer authorised to treat COVID-19 in any
US region. However, we will continue to discuss future
opportunities to support governments, healthcare systems, and
patients whereby our COVID-19 solutions can address the emergence
of any new COVID-19 variant of concern.
All
expectations, guidance and targets regarding future performance and
dividend payments should be read together with ‘Guidance,
assumptions and cautionary statements’ on page 43. If
exchange rates were to hold at the closing rates on 31 March 2022
($1.31/£1, €1.18/£1 and Yen 160/£1) for the
rest of 2022, the estimated positive impact on 2022 Sterling
turnover growth for new GSK would be 2% and if exchange gains or
losses were recognised at the same level as in 2021, the estimated
positive impact on 2022 Sterling Adjusted Operating Profit growth
for new GSK would be 3%.
|
|
Results presentation
|
|
A
webcast of the quarterly results presentation hosted by Emma
Walmsley, GSK CEO, will be held at 12pm BST on 27 April 2022.
Presentation materials will be published on www.gsk.com prior to
the webcast and a transcript of the webcast will be published
subsequently.
Information
available on GSK’s website does not form part of, and is not
incorporated by reference into, this Results
Announcement.
|
|
Operating performance – Q1 2022
|
|
Turnover
|
||||||
|
|
Q1
2022
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Specialty
Medicines
|
3,135
|
|
98
|
|
97
|
|
|
Vaccines
|
1,669
|
|
36
|
|
36
|
|
|
General
Medicines
|
2,343
|
|
2
|
|
3
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
7,147
|
|
40
|
|
40
|
|
|
|
|
|
|
|
|
|
|
Consumer
Healthcare
|
2,633
|
|
14
|
|
14
|
|
|
|
|
|
|
|
|
|
|
Group
turnover
|
9,780
|
|
32
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Total
turnover in the quarter was £9,780 million, up 32% AER, 32%
CER, reflecting a strong performance in Commercial Operations in
the three product groups and Consumer Healthcare. Sales of
Xevudy were £1,307
million and contributed 25 percentage points of growth in the
quarter to Commercial Operations. Specialty Medicines included the
positive impact of international tender phasing, Vaccines benefited
from Shingrix post-pandemic
recovery and retail buy-in in the US and General Medicines
reflected growth from Trelegy and recovery of the antibiotics
market.
Specialty
Medicines turnover was £3,135 million, up 98% AER, 97% CER,
driven by consistent growth in all therapy areas including sales of
Xevudy. Sales growth was up
16% AER, 15% CER excluding Xevudy.
Vaccines
turnover grew 36% AER, 36% CER to £1,669 million, driven
primarily by Shingrix in
the US and Europe reflecting strong performance and the benefit of
a favourable comparator in Q1 2021 when sales were impacted by
COVID-19 related disruptions in several markets and lower Centre
for Disease Control (CDC) purchases.
General
Medicines turnover was £2,343 million, up 2% AER, 3% CER, with
growth from Trelegy in all
regions, recovery of the antibiotics market and the benefit of a
favourable prior period returns and rebates (RAR) adjustment,
offsetting the impact of generic competition in US, Europe and
Japan.
Consumer Healthcare grew 14% AER, 14% CER to £2,633 million.
Total sales grew 15% AER, 16% CER, excluding the impact of brands
divested, with strong growth across all categories.
Operating profit
Total
operating profit was £2,801 million compared with £1,693
million in Q1 2021. This included £924 million upfront
settlement income from Gilead, increased profits on turnover growth
of 32% at CER, partly offset by higher remeasurement charges for
contingent consideration liabilities and lower profits on
disposals. Adjusted operating profit was £2,613 million, 39%
higher than Q1 2021 at AER and at CER. The Adjusted operating
margin of 26.7% was 1.4 percentage points higher at AER and 1.3
percentage points higher on a CER basis than in Q1 2021. The
benefit from COVID-19 solutions sales (Xevudy) contributed approximately 11%
AER, 11% CER to Adjusted Operating profit growth.
Earnings per share
Total
EPS was 35.9p compared with 21.5p in Q1 2021. This primarily
reflected leverage from significant sales growth during the
quarter, with the upfront income of £924 million from the
settlement with Gilead partly offset by an increase in finance
costs.
Adjusted
EPS was 32.8p compared with 22.9p in Q1 2021, up 43% at AER, 43%
CER, on a 39% CER increase in Adjusted operating profit primarily
reflecting sales of Specialty Medicines and Vaccines, including
COVID-19 solutions sales, tight cost control and a lower effective
tax rate. These were partly offset by higher supply chain costs,
increased R&D investment, favourable legal settlements in Q1
2021 and higher interest costs. The contribution to growth from
COVID-19 solutions was approximately 15% at AER, 15% at
CER.
Cash flow
The
cash generated from operations for the quarter was £2,755
million (Q1 2021: £486 million). The increase primarily
reflected a significant increase in operating profit including the
upfront income from the settlement with Gilead, favourable timing
of collections and profit share payments for Xevudy sales and a lower seasonal
increase in inventory.
|
|
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
Regulatory approvals or other regulatory action
|
Cabenuva
|
FLAIR (HIV, optional oral lead-in)
|
Regulatory approval (US)
|
|
Cabenuva
|
MOCHA (HIV, adolescent)
|
Regulatory approval (US)
|
|
|
Triumeq
|
HIV, paediatric, dispersible tablet
|
Regulatory approval (US)
|
|
|
Benlysta
|
BLISS-LN (lupus nephritis, intravenous)
|
Regulatory approval (China)
|
|
|
Nucala
|
Severe eosinophilic asthma, 40 mg prefilled syringe
for
6-11 year olds
|
Positive CHMP opinion (EU)
|
|
|
Covifenz (Medicago)
|
COVID-19
|
Regulatory approval (CA)
|
|
|
Regulatory submissions or acceptances
|
daprodustat
|
ASCEND (anaemia of chronic kidney disease)
|
Regulatory filing acceptance (US, EU)
|
|
COVID-19 vaccine candidate (Sanofi)
|
COVID-19
|
Regulatory submission (EU)
|
|
|
Phase III data readouts or other significant events
|
RSV maternal vaccine candidate
|
GRACE (RSV, maternal)
|
Stopped enrolment and vaccination
|
|
COVID-19 vaccine candidate (Sanofi)
|
COVID-19
|
Positive phase III data
|
|
Anticipated news flow
|
|
Timing
|
Medicine/vaccine
|
Trial (indication, presentation)
|
Event
|
|
H1 2022
|
bepirovirsen
|
B-Clear (Hepatitis B virus)
|
Phase IIb data readout
|
|
RSV older adults vaccine candidate
|
RSV, older adults
|
Phase III data readout
|
|
|
COVID-19 vaccine candidate (Sanofi)
|
COVID-19
|
Regulatory submission (US)
|
|
|
COVID-19 vaccine candidate (SK Bioscience)
|
COVID-19
|
Phase III data readout
|
|
|
COVID-19 vaccine candidate (SK Bioscience)
|
COVID-19
|
Regulatory submission (EU)
|
|
|
H2 2022
|
otilimab
|
contRAst programme (rheumatoid arthritis)
|
Phase III data readout
|
|
Blenrep
|
DREAMM-3 (3L+ multiple myeloma)
|
Phase III data readout
|
|
|
Blenrep
|
DREAMM-3 (3L+ MM)
|
Regulatory submission (US, EU)
|
|
|
Jemperli
|
RUBY (1L endometrial cancer)
|
Phase III data readout (interim analysis)
|
|
|
gepotidacin
|
EAGLE (uncomplicated urinary tract infection)
|
Phase III data readout (interim analysis)
|
|
|
MenABCWY (gen 1) vaccine candidate
|
MenABCWY
|
Phase III data readout
|
|
|
RSV older adults vaccine candidate
|
RSV, older adults
|
Regulatory submission (US)
|
|
|
Priorix
|
Measles-mumps-rubella
|
Regulatory decision (US)
|
|
|
Menveo
|
Invasive meningococcal disease, liquid formulation
|
Regulatory decision (US)
|
|
|
Rotarix
|
Rotavirus, liquid formulation
|
Regulatory decision (US)
|
|
|
COVID-19 vaccine candidate (SK Bioscience)
|
COVID-19
|
Regulatory decision (EU)
|
|
|
COVID-19 vaccine candidate (Sanofi)
|
COVID-19
|
Regulatory decision (US)
|
|
|
Covifenz (Medicago)
|
COVID-19
|
Regulatory submission (US)
|
|
|
2023
|
otilimab
|
contRAst programme (rheumatoid arthritis)
|
Regulatory submission (US, EU)
|
|
daprodustat
|
ASCEND (anaemia of chronic kidney disease)
|
Regulatory decision (US, EU)
|
|
|
linerixibat
|
GLISTEN (cholestatic pruritus in primary biliary
cholangitis)
|
Phase III data readout
|
|
|
Blenrep
|
DREAMM-3 (3L+ MM)
|
Regulatory decision (US, EU)
|
|
|
Blenrep
|
DREAMM-8 (2L+ MM)
|
Phase III data readout
|
|
|
Blenrep
|
DREAMM-8 (2L+ MM)
|
Regulatory submission (US, EU)
|
|
|
Blenrep
|
DREAMM-7 (2L+ MM)
|
Phase III data readout
|
|
|
Blenrep
|
DREAMM-7 (2L+ MM)
|
Regulatory submission (US, EU)
|
|
|
Jemperli
|
RUBY (1L endometrial cancer)
|
Regulatory submission (US, EU)
|
|
|
letetresgene-autoleucel
|
IGNYTE-ESO (2L+ synovial sarcoma)
|
Phase II data readout
|
|
|
RSV older adults vaccine candidate
|
RSV, older adults
|
Regulatory decision (US)
|
|
|
MenABCWY (gen 1) vaccine candidate
|
MenABCWY
|
Regulatory submission (US)
|
|
|
Malaria (fractional dose) vaccine
|
Malaria
|
Phase II data readout
|
|
|
Covifenz (Medicago)
|
COVID-19
|
Regulatory decision (US)
|
|
Refer
to pages 34 to 41 for further details on several key medicines and
vaccines in development by therapy area.
|
|
Contents
|
Page
|
|
|
|
|
Q1 2022
R&D pipeline highlights
|
4
|
|
Financial
performance
|
7
|
|
Commercial
Operations turnover – three months ended 31 March
2022
|
8
|
|
Consumer
Healthcare turnover – three months ended 31 March
2022
|
11
|
|
Cash
generation
|
18
|
|
Returns
to shareholders
|
19
|
|
Total
and Adjusted results
|
20
|
|
Income
statement – three months ended 31 March 2022
|
22
|
|
Statement
of comprehensive income
|
23
|
|
Balance
sheet
|
26
|
|
Statement
of changes in equity
|
27
|
|
Cash
flow statement – three months ended 31 March
2022
|
28
|
|
Segment
information
|
29
|
|
Legal
matters
|
30
|
|
Additional
information
|
31
|
|
Reconciliation
of cash flow to movements in net debt
|
33
|
|
Net
debt analysis
|
33
|
|
Free
cash flow reconciliation
|
33
|
|
R&D
commentary
|
34
|
|
Reporting
definitions
|
42
|
|
Guidance,
assumptions and cautionary statements
|
43
|
|
Independent
review report
|
44
|
|
Contacts
|
|
GSK is
a science-led global healthcare company. For further information
please visit www.gsk.com/aboutus.
|
|
GSK enquiries:
|
|
|
|
|
Media
enquiries:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington)
|
|
|
|
|
|
|
Analyst/Investor
enquiries:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
7881 269066
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Joshua
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
589 3774
|
(Philadelphia)
|
|
|
Frances
De Franco
|
+1 570
236 4850
|
(Philadelphia)
|
|
|
Sonya
Ghobrial
|
+44 (0)
7392 784784
|
(Consumer)
|
|
|
Emma
White
|
+44 (0)
7823 523562
|
(Consumer)
|
|
|
Rakesh
Patel
|
+44 (0)
7552 484646
|
(Consumer)
|
|
|
|
|
|
|
Registered
in England & Wales:
No.
3888792
|
|||
|
|
|||
|
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8
9GS
|
|||
|
Financial performance – Q1
2022
|
|
Total results
|
|
The
Total results for the Group are set out below.
|
|
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
9,780
|
|
7,418
|
|
32
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(3,690)
|
|
(2,480)
|
|
49
|
|
49
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
6,090
|
|
4,938
|
|
23
|
|
24
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,844)
|
|
(2,427)
|
|
17
|
|
18
|
|
Research
and development
|
(1,167)
|
|
(1,118)
|
|
4
|
|
4
|
|
Royalty income
|
139
|
|
91
|
|
53
|
|
53
|
|
Other
operating income
|
583
|
|
209
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating
profit
|
2,801
|
|
1,693
|
|
65
|
|
65
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
10
|
|
10
|
|
|
|
|
|
Finance
expense
|
(212)
|
|
(201)
|
|
|
|
|
|
Share
of after tax (losses)/profits of associates
and
joint ventures
|
(1)
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,598
|
|
1,518
|
|
71
|
|
71
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(431)
|
|
(258)
|
|
|
|
|
|
Tax rate %
|
16.6%
|
|
17.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
2,167
|
|
1,260
|
|
72
|
|
72
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
365
|
|
187
|
|
|
|
|
|
Profit
attributable to shareholders
|
1,802
|
|
1,073
|
|
68
|
|
67
|
|
|
|
|
|
|
|
|
|
|
|
2,167
|
|
1,260
|
|
72
|
|
72
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
35.9p
|
|
21.5p
|
|
67
|
|
66
|
|
|
|
|
|
|
|
|
|
|
Adjusted results
|
|
The
Adjusted results for the Group are set out below. Reconciliations
between Total results and Adjusted results for Q1 2022 and Q1 2021
are set out on page 15. Definition of the Adjusted results are set
out on page 20.
|
|
|
Q1 2022
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
9,780
|
|
100
|
|
32
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Cost of
sales
|
(3,471)
|
|
(35.5)
|
|
55
|
|
55
|
|
Selling,
general and administration
|
(2,681)
|
|
(27.4)
|
|
16
|
|
17
|
|
Research
and development
|
(1,154)
|
|
(11.8)
|
|
7
|
|
7
|
|
Royalty
income
|
139
|
|
1.4
|
|
53
|
|
53
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,613
|
|
26.7
|
|
39
|
|
39
|
|
|
|
|
|
|
|
|
|
|
Adjusted
profit before tax
|
2,410
|
|
|
|
41
|
|
41
|
|
Adjusted
profit after tax
|
1,979
|
|
|
|
42
|
|
43
|
|
Adjusted
profit attributable to shareholders
|
1,646
|
|
|
|
44
|
|
44
|
|
|
|
|
|
|
|
|
|
|
Adjusted
earnings per share
|
32.8p
|
|
|
|
43
|
|
43
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|
|
Q1 2022
£m
|
|
%
of
turnover
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
3,121
|
|
43.7
|
|
27
|
|
27
|
|
Research
and Development
|
(1,095)
|
|
|
|
6
|
|
6
|
|
Consumer
Healthcare
|
650
|
|
24.7
|
|
21
|
|
26
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,676
|
|
27.4
|
|
37
|
|
38
|
|
Corporate
& other unallocated costs
|
(63)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,613
|
|
26.7
|
|
39
|
|
39
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
|
Commercial Operations
|
|
|
Q1 2022
|
||||
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
HIV
|
1,181
|
|
15
|
|
14
|
|
Oncology
|
127
|
|
15
|
|
15
|
|
Immuno-inflammation,
respiratory and other
|
520
|
|
18
|
|
18
|
|
Pandemic
|
1,307
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
Specialty Medicines
|
3,135
|
|
98
|
|
97
|
|
|
|
|
|
|
|
|
Meningitis
|
212
|
|
12
|
|
12
|
|
Influenza
|
18
|
|
-
|
|
-
|
|
Shingles
|
698
|
|
>100
|
|
>100
|
|
Established
Vaccines
|
741
|
|
8
|
|
8
|
|
Pandemic
Vaccines
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
Vaccines
|
1,669
|
|
36
|
|
36
|
|
|
|
|
|
|
|
|
Respiratory
|
1,535
|
|
3
|
|
3
|
|
Other
General Medicines
|
808
|
|
-
|
|
3
|
|
|
|
|
|
|
|
|
General Medicines
|
2,343
|
|
2
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial Operations
|
7,147
|
|
40
|
|
40
|
|
|
|
|
|
|
|
|
US
|
3,586
|
|
62
|
|
57
|
|
Europe
|
1,660
|
|
32
|
|
36
|
|
International
|
1,901
|
|
17
|
|
20
|
|
|
|
|
|
|
|
|
Commercial Operations by region
|
7,147
|
|
40
|
|
40
|
|
|
|
|
|
|
|
|
Total
turnover in the quarter was £7,147 million, up 40% AER, 40%
CER, reflecting strong performance in all three product groups.
Specialty Medicines included the positive impact of international
tender phasing, sales of Xevudy were £1,307 million and
contributed 25 percentage points of growth in the quarter. Vaccines
benefited from Shingrix
post pandemic recovery and retail buy-in in the US. General
Medicines reflects recovery of the antibiotics market as well as
the benefit of a favourable prior period RAR
adjustment.
Specialty Medicines
Specialty
Medicines sales in the quarter were £3,135 million, up 98%
AER, 97% CER, driven by consistent growth in all therapy areas
including sales of Xevudy.
Sales growth was up 16% AER, 15% CER excluding Xevudy.
HIV
HIV
sales were £1,181 million with growth of 15% AER, 14% CER in
the quarter. Growth was driven by new HIV products Dovato, Cabenuva, Rukobia, Juluca and Apretude and phasing. Phasing
contributed approximately two thirds of the growth, driven by
Tivicay International
tenders, US customer ordering patterns and US channel inventory
movement.
New HIV
products delivered sales of £446 million up 70% AER, 69% CER,
representing 38% of the total HIV portfolio. Sales of the oral two
drug regimens Dovato and
Juluca were £257
million and £133 million respectively with combined growth of
54% AER, 53% CER. Cabenuva,
the first long acting injectable, recorded quarterly sales of
£38 million. Apretude
delivered sales of £2 million.
Oncology
Oncology
sales in the quarter were £127 million, up 15% AER, 15% CER.
Zejula sales of £98
million, up 11% AER, 11% CER, continue to be adversely impacted by
diagnosis rates, particularly in the US. Sales of Blenrep, grew 19% AER, 19% CER to
£25 million in the quarter.
Immuno-inflammation,
Respiratory and Other
Immuno-inflammation,
Respiratory and Other sales were £520 million up 18% AER, 18%
CER. Benlysta sales were
£215 million, up 21% AER, 18% CER with growth in all regions,
including International sales of £26 million up 53% AER, 53%
CER. Nucala sales were
£295 million, up 16% AER, 16% CER including US sales of
£177 million up 18% AER, 15% CER on continued strong demand
and additional indications approval and launch. International
Nucala sales were £53
million up 26% AER, 31% CER.
Pandemic
Sales
of Xevudy were £1,307
million, with no sales in Q1 last year given launch in Q2 2021.
Sales were delivered in all regions, comprising US £770
million, Europe £311 million and International £226
million.
Vaccines
Vaccines
turnover grew 36% AER, 36% CER to £1,669 million, driven
primarily by Shingrix in
the US and Europe reflecting strong performance and the benefit of
a favourable comparator to Q1 2021 when sales were impacted by
COVID-19 related disruptions in several markets and lower CDC
purchases.
Meningitis
Meningitis
vaccines sales grew 12% AER, 12% CER% to £212 million mainly
driven by Bexsero (22% AER,
23% CER to £163 million) reflecting higher CDC purchasing in
the US.
Shingles
Shingrix grew >100% AER, >100 CER% to £698
million, primarily due to channel inventory build-up and demand
recovery in the US and higher demand in Germany. Launch markets
also contributed to increased sales reflecting continued geographic
expansion.
Established
Vaccines
Established
Vaccines grew 8% AER, 8% CER to £741 million mainly as a
result of higher CDC purchases of Infanrix/Pediarix and Hepatitis vaccines, US
demand and share growth for Boostrix, partially offset by lower
Synflorix, Cervarix and MMRV sales in
International.
General Medicines
General
Medicines sales in the quarter were £2,343 million, up 2% AER,
3% CER, with growth from Trelegy in all regions and the benefit
of a favourable prior period RAR adjustment, offsetting the impact
of generic competition in US, Europe and Japan.
Respiratory
Respiratory
sales were £1,535 million, up 3% AER, 3% CER. Trelegy sales were £340 million,
up 37% AER, 35% CER with strong growth in all regions. Advair/Seretide sales of £302 million
were down 14% AER, 14% CER on US and Europe generic competition,
partially offset by growth in International on targeted
promotion.
Other General
Medicines
Other
General Medicines sales were £808 million, flat at AER, up 3%
CER. Augmentin sales were
£129 million, up 42% AER, 51% CER reflecting rebound of the
antibiotic market post pandemic in the International and Europe
regions and in the US, a favourable prior period RAR adjustment was
reflected. This offsets ongoing impact of generic competition and
approximately two percentage points impact from the divestment of
GSK’s cephalosporin products in Q4 2021.
By
Region
US
In the
US, sales were £3,586 million, up 62% AER, 57% CER, including
Xevudy sales of £770
million contributing 34 percentage points of growth. HIV sales of
£697 million up 17% AER, 13% CER were driven by growth of new
HIV products, customer ordering patterns and lower channel
inventory burn. New HIV products delivered sales of £285
million up 72% AER, 66% CER, driven by Dovato and Cabenuva. Nucala and Benlysta both continued to grow
double-digits despite some year-end wholesaler destocking, while
Oncology growth continued to be impacted by diagnosis
rates.
Vaccine
sales were £892 million, up 77% AER, 71% CER. Growth was
driven by Shingrix
reflecting demand recovery and retail buy-in ahead of a price
increase. Meningitis, Hepatitis, Infanrix/Pediarix and Boostrix sales all grew in the quarter
reflecting CDC purchasing patterns and demand recovery. General
Medicines sales were £811 million up 7% AER, 4% CER,
benefiting from a favourable prior period RAR adjustment.
Trelegy sales continued
strong performance on growth of the single inhaler triple therapy
market and demand.
Europe
In
Europe, sales were £1,660 million, up 32% AER, 36% CER,
including Xevudy sales of
£311 million contributing 25 percentage points of growth. HIV
sales were £299 million up 4% AER, 8% CER driven by
Dovato. Strong double-digit
growth continued in the quarter on Benlysta, Nucala and Oncology
assets.
Vaccine
sales were £409 million, up 33% AER, 38% CER. Growth was
driven by Shingrix sales of
£160 million, up >100% AER, >100% CER on strong demand
in Germany post pandemic and channel re-stocking. General Medicines
sales were £503 million down 7% AER, 4% CER, with ongoing
generic competitive pressures on Seretide, partly offset by strong
demand for Trelegy and
growth of Augmentin on
rebound of the antibiotic market post the pandemic.
International
International
sales were £1,901 million, up 17% AER, 20% CER, including
Xevudy sales of £226
million contributing 14 percentage points of growth. HIV sales were
£185 million up 26% AER, 30% CER primarily driven by tender
phasing. Combined Tivicay
and Triumeq sales were
£148 million with growth of 21% AER and 25% CER. Nucala and Benlysta both continued to grow
strongly, due to Japan’s biologicals market growth and
China’s National Reimbursement Drug List approval,
respectively.
Vaccine
sales were £368 million, down 11% AER, 9% CER primarily
reflecting phasing of public tenders. General Medicines sales were
£1,029 million up 2% AER, 6% CER. Respiratory sales of
£480 million were up 1% AER, 4% CER. Strong growth of
Trelegy in Japan, China and
Canada, and growth of Seretide on targeted promotion, offset
impact of generic competition and lower allergy season in Japan.
Other General Medicines sales of £549 million, up 4% AER, 8%
CER reflect growth of Augmentin on rebound of the antibiotic
market post the pandemic.
|
|
Consumer Healthcare turnover
|
|
|
|
|
Q1 2022
|
||||
|
|
|
|
|
|
|
|
|
|
|
|
|
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Oral
health
|
|
|
740
|
|
6
|
|
9
|
|
Pain
relief
|
|
|
639
|
|
17
|
|
17
|
|
Vitamins,
minerals and supplements
|
|
|
407
|
|
17
|
|
15
|
|
Respiratory
health
|
|
|
370
|
|
51
|
|
53
|
|
Digestive
health and other
|
|
|
477
|
|
-
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare
|
|
|
2,633
|
|
14
|
|
14
|
|
|
|
|
|
|
|
|
|
|
US
|
|
|
857
|
|
20
|
|
17
|
|
Europe
|
|
|
627
|
|
4
|
|
8
|
|
International
|
|
|
1,149
|
|
15
|
|
17
|
|
|
|
|
|
|
|
|
|
|
Consumer Healthcare by region
|
|
|
2,633
|
|
14
|
|
14
|
|
|
|
|
|
|
|
|
|
|
In Q1 2022, Consumer Healthcare turnover grew 14% AER, 14% CER to
£2,633 million. Sales grew 15% AER, 16% CER, excluding the
impact of brands divested, which were entirely in the Digestive
health and other category.
Overall, the business delivered strong growth across all
categories. Sales benefited from favourable prior year comparators
especially in Respiratory health which saw a strong rebound
following the historically low cold and flu season in Q1 2021, with
cold and flu sales contributing approximately five percentage
points to total growth. In addition, advance retailer and
wholesaler stock-in, and initial distributor sell-in due to the
systems cutover and distribution business model change ahead of the
demerger contributed approximately two percentage points to total
growth. Strong sales growth in Pain relief benefited from increased
demand during the Omicron wave and an improved capacity in
Vitamins, minerals and supplements.
Oral
health
Oral health sales grew 6% AER, 9% CER to £740 million.
Sensodyne
delivered high-single digit growth
reflecting underlying brand strength, continued innovation and
strong growth across key markets including the US, India, Japan,
Middle East and Africa. Paradontax delivered low double-digit growth. Denture care
grew low-teens percent following the decrease of sales during the
pandemic.
Pain
relief
Pain relief sales increased 17% AER, 17% CER to £639
million. Panadol grew mid thirties percent due to a successful
campaign aimed at post vaccination use and increased demand during
the Omicron wave. Advil grew low thirties percent benefitting from retail
stocking patterns in the US versus a decrease in Q1 2021.
Excedrin
grew high-single digits and
Voltaren
was stable with growth in China offset
by a decrease in Germany.
Vitamins, minerals and
supplements
Vitamins,
minerals and supplements sales increased 17% AER, 15% CER to
£407 million. Centrum
grew high-teens percent, with particularly strong growth in China
due to consumer focus on immunity as a result of the pandemic.
Emergen-C grew high
thirties percent versus a high twenties percent decrease in Q1
2021. Caltrate
decreased
low single digits, high single digit growth in China was
insufficient to offset a decline in the US and South East
Asia.
Respiratory
health
Respiratory health sales increased 51% AER, 53% CER to £370
million. The category rebounded strongly from the historically low
demand for cold and flu products in Q1 2021. Cold and flu product
sales growth doubled in the US and was strong in Europe, Middle
East and Africa and Latin America, with sales ahead of pre-pandemic
levels in 2019.
Digestive health and
other
Digestive health and other brands were flat AER, down 1% CER to
£477 million. Sales grew 5% AER, 4% CER excluding the impact
of brands divested. Digestive health increased high-single digits
with strong growth in Tums and Eno partially offset by a low-single digit decrease
in Nexium. Smokers health also grew high-single digits and
Skin health grew low single-digits.
By
Region
International and US sales grew high-teens percent on a CER basis
with broad growth across categories. European growth was driven by
a particularly strong rebound of cold and flu product sales ahead
of pre-pandemic sales in 2019.
|
|
Operating
performance
|
|
Cost of sales
Total
cost of sales as a percentage of turnover was 37.7%, 4.3 percentage
points higher at AER and 4.2 percentage points higher in CER terms
than Q1 2021. This included lower write-downs on sites from major
restructuring programmes compared to 2021.
Excluding
these and other Adjusting items, Adjusted cost of sales as a
percentage of turnover was 35.5%, 5.3 percentage points higher at
AER and at CER compared with Q1 2021. This primarily reflected
higher pandemic sales (Xevudy) increasing cost of sales margin
by seven percentage points as well as the impact of increased
commodity prices and freight costs particularly in Consumer
Healthcare. This was partially offset by a favourable mix primarily
from increased sales of Shingrix in the US and Europe as well
as a one-time benefit
from inventory adjustments in the quarter.
Selling, general and administration
Total
SG&A costs as a percentage of turnover were 29.1%, 3.6
percentage points lower at AER and 3.5 percentage points lower at
CER than in Q1 2021 as the growth in sales outweighed SG&A
expenditure growth.
Adjusted
SG&A costs as a percentage of turnover were 27.4%, 3.8
percentage points lower at AER than in Q1 2021 and 3.6 percentage
points lower at CER. Adjusted SG&A costs increased 16% AER, 17%
CER which primarily reflected an increased level of launch
investment in Specialty Medicines particularly HIV, Vaccines and
increased Consumer Healthcare brand investment to a more normal
level compared to challenging conditions in Q1 2021. The growth in
Adjusted SG&A also reflected an unfavourable comparison to a
beneficial legal settlement in 2021, exchange losses on
collaboration profit share and impairment provisions relating to
Russia and Ukraine. This growth, however was partly offset by the
continuing benefit of restructuring and tight control of ongoing
costs.
Research and development
Group
R&D expenditure was £1,167 million (11.9% of turnover), up
4% at both AER and CER. Adjusted R&D expenditure was
£1,154 million (11.8% of turnover), 7% higher than Q1 2021 at
both AER and CER.
Adjusted
R&D expenditure excluding Consumer Healthcare was £1,088
million (15.2% of turnover), 6% higher at AER, 6% higher at CER,
primarily driven by increases in the Vaccines portfolio. Specialty
Medicines investment decreased with reductions in the late-stage
Specialty Medicines portfolio partly offset by increased research
investment.
In the
Vaccines portfolio there has been increased investment in RSV for
older adults and meningitis due to the ongoing phase III trials
which commenced in 2021 and in Shingrix due to the combination trial
exploring the co-administration of Shingrix/Flu/COVID-19 as well as
further market expansion. There has also been a significant
increase in the level of mRNA investment.
In
Specialty Medicines investment continues in Blenrep, Zejula and otilimab but
decreased primarily following termination of the Oncology assets
bintrafusp alpha and feladilimab in 2021 and following the
regulatory submission of daprodustat during Q1 2022. GSK continues
to see increased investment in Specialty Medicines due to several
early-stage assets progressing to phase I.
Consumer
Healthcare adjusted R&D spend was £66 million in the
quarter.
Royalty income
Royalty income was £139 million (Q1 2021: £91 million),
up 53% AER, 53% CER, primarily reflecting higher sales of Gardasil
and royalty income from Gilead under the settlement and licensing
agreement with Gilead announced on 1 February 2022 (see page
21).
|
|
Other operating income/(expense)
Net
other operating income was £583 million (Q1 2021: £209
million) including £924 million upfront income received from
the settlement with Gilead. This was partly offset by accounting
charges of £335 million (Q1 2021: £107 million) arising
from the re-measurement of contingent consideration liabilities and
the liabilities for the Pfizer put option and Pfizer and Shionogi
preferential dividends in ViiV Healthcare. This included a
re-measurement charge of £256 million (Q1 2021: £134
million) for the contingent consideration liability due to Shionogi
& Co. Limited (Shionogi), including the unwinding of the
discount for £101 million and a charge for £155 million
primarily from changes to exchange rates as well as adjustments to
sales forecasts.
|
|
Operating profit
Total
operating profit was £2,801 million compared with £1,693
million in Q1 2021. This included the £924 million upfront
settlement income from Gilead as well as increased profits on
turnover growth of 32% at CER, partly offset by higher
remeasurement charges for contingent consideration liabilities and
lower profits on disposals.
Adjusted
operating profit was £2,613 million, 39% higher than Q1 2021
at AER and at CER on a turnover increase of 32% CER. The Adjusted
operating margin of 26.7% was 1.4 percentage points higher at AER
and 1.3 percentage points higher at CER than in Q1 2021. This
primarily reflected sales growth of 32% CER which was significantly
higher than growth in SG&A and R&D with continued tight
cost control and restructuring benefits. The benefit from COVID-19
solutions sales (Xevudy)
contributed approximately 11% AER, 11% CER to Adjusted Operating
profit growth.
Excluding
Consumer Healthcare, Adjusted operating profit was £1,963
million, 46% higher than Q1 2021 at AER and 44% at CER and the
Adjusted operating margin was 27.5% which was 1.1 percentage points
higher at AER and 0.8 percentage points higher at CER than in Q1
2021. This primarily reflected the benefit from COVID-19 solutions
sales (Xevudy), which
contributed approximately 16% AER, 15% CER to Adjusted operating
profit growth and reduced the Adjusted operating margin by
approximately 2.6 percentage points at AER and 2.5 percentage
points at CER. Adjusted operating profit growth also includes
leverage from strong sales growth with margin improvement from
sales mix, primarily Shingrix.
Contingent
consideration cash payments made to Shionogi and other companies
reduce the balance sheet liability and hence are not recorded in
the income statement. Total contingent consideration cash payments
in Q1 2022 amounted to £211 million (Q1 2021: £221
million). These included cash payments made to Shionogi of
£208 million (Q1 2021: £216 million).
Adjusted operating profit by business
Commercial
Operations operating profit was £3,121 million, up 27% AER and
CER on a turnover increase of 40% CER. The operating margin of
43.7% was 4.3 percentage points lower at both AER and CER than in
Q1 2021. This primarily reflected strong sales of lower margin
Xevudy in the quarter,
increased investment behind launches in Specialty Medicines
including HIV and Vaccines plus higher commodity, freight and
distribution costs as well as an adverse comparison to a favourable
legal settlement in Q1 2021. This was partly offset by continued
tight control of ongoing costs, benefits from continued
restructuring and increased royalty income from Gardasil sales and,
following the settlement with Gilead in February 2022, Biktarvy
sales.
R&D
segment operating expenses were £1,095 million, up 6% AER, 6%
CER, primarily driven by increased investment in Vaccines including
priority investments for RSV Older Adult, MenABCWY and
mRNA.
Consumer
Healthcare operating profit was £650 million, up 21% AER, 26%
CER on a turnover increase of 14% CER. The operating margin of
24.7% was 1.5 percentage points higher at AER and 2.3 percentage
points higher on a CER basis than in Q1 2021. This reflected strong
leverage from volume growth and price increases, supply chain
efficiencies and incremental synergy benefits from the Pfizer Joint
Venture partially offset by increased brand investment, increased
commodity and freight costs as well as new costs in 2022 associated
with starting to run Consumer Healthcare as a standalone
company.
Net finance costs
Total
net finance costs were £202 million compared with £191
million in Q1 2021. Adjusted net finance costs were £202
million compared with £190 million in Q1 2021. The increase
primarily reflected higher interest expense on debt due to adverse
movements in exchange rates and the newly issued Consumer
Healthcare bond debt.
Share of after tax profits of associates and joint
ventures
The
share of after tax loss of associates and joint ventures was
£1 million (Q1 2021: £16 million profit).
Taxation
The
charge of £431 million represented an effective tax rate on
Total results of 16.6% (Q1 2021: 17.0%) and reflected the different
tax effects of the various Adjusting items. Tax on Adjusted profit
amounted to £431 million and represented an effective Adjusted
tax rate of 17.9% (Q1 2021: 18.6%).
Issues
related to taxation are described in Note 14,
‘Taxation’ in the Annual Report 2021. The Group
continues to believe it has made adequate provision for the
liabilities likely to arise from periods that are open and not yet
agreed by relevant tax authorities. The ultimate liability for such
matters may vary from the amounts provided and is dependent upon
the outcome of agreements with relevant tax
authorities.
Non-controlling interests
The
allocation of Total earnings to non-controlling interests amounted
to £365 million (Q1 2021: £187 million). The increase was
primarily due to an increased allocation of ViiV Healthcare profits
of £227 million (Q1 2021: £76 million), including the
Gilead upfront settlement income partly offset by increased credits
for re-measurement of contingent consideration
liabilities.
The
allocation of Adjusted earnings to non-controlling interests
amounted to £333 million (Q1 2021: £246 million). The
increase in allocation primarily reflected an increase in
allocation of Consumer Healthcare Joint Venture profits of
£154 million (Q1 2021: £114 million) and an increase
allocation of ViiV Healthcare profits of £113 million (Q1
2021: £108 million), as well as higher net profits in some of
the Group’s other entities with non-controlling
interests.
Earnings per share
Total
EPS was 35.9p compared with 21.5p in Q1 2021. This primarily
reflected leverage from significant sales growth during the quarter
and income of £924 million from the settlement with Gilead
partly offset by an increase in finance costs.
Adjusted
EPS was 32.8p compared with 22.9p in Q1 2021, up 43% AER 43% CER,
on a 39% CER increase in Adjusted operating profit primarily
reflecting increased sales of Specialty Medicines and Vaccines
including COVID-19 solutions sales, tight cost control and a lower
effective tax rate. These were partly offset by higher supply chain
costs, increased R&D investment, favourable legal settlements
in Q1 2021 and higher interest costs. The contribution to growth
from COVID-19 solutions was approximately 15% AER, 15%
CER.
Currency impact on Q1 2022 results
The
results for Q1 2022 are based on average exchange rates,
principally £1/$1.34, £1/€1.19 and £1/Yen 156.
Comparative exchange rates are given on page 31. The period-end
exchange rates were £1/$1.31, £1/€1.18 and
£1/Yen 160.
In Q1
2022, turnover was up 32% AER and CER. Total EPS was 35.9p compared
with 21.5p in Q1 2021. Adjusted EPS was 32.8p compared with 22.9p
in Q1 2021, up 43% at both AER and CER. The currency impact was
largely neutral reflecting the strengthening in Sterling against
the Euro and Japanese Yen offset by the weakening of Sterling
against the US Dollar. Exchange gains or losses on the settlement
of intercompany transactions had a one percent favourable impact on
the neutral currency impact on Adjusted EPS.
|
|
Adjusting items
The
reconciliations between Total results and Adjusted results for Q1
2022 and Q1 2021 are set out below.
|
|
Three months ended 31 March 2022
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Sepa-
ration
costs
£m
|
|
Adjusted
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
9,780
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,780
|
|
Cost of
sales
|
(3,690)
|
|
174
|
|
17
|
|
16
|
|
12
|
|
|
|
|
|
(3,471)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
6,090
|
|
174
|
|
17
|
|
16
|
|
12
|
|
|
|
|
|
6,309
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,844)
|
|
|
|
|
|
37
|
|
|
|
9
|
|
117
|
|
(2,681)
|
|
Research
and development
|
(1,167)
|
|
23
|
|
(16)
|
|
6
|
|
|
|
|
|
|
|
(1,154)
|
|
Royalty
income
|
139
|
|
|
|
|
|
|
|
|
|
|
|
|
|
139
|
|
Other
operating income/(expense)
|
583
|
|
|
|
|
|
|
|
335
|
|
(940)
|
|
22
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
2,801
|
|
197
|
|
1
|
|
59
|
|
347
|
|
(931)
|
|
139
|
|
2,613
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(202)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(202)
|
|
Share
of after tax losses of
associates
and joint ventures
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
2,598
|
|
197
|
|
1
|
|
59
|
|
347
|
|
(931)
|
|
139
|
|
2,410
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(431)
|
|
(40)
|
|
1
|
|
(14)
|
|
(53)
|
|
132
|
|
(26)
|
|
(431)
|
|
Tax rate %
|
16.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17.9%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
2,167
|
|
157
|
|
2
|
|
45
|
|
294
|
|
(799)
|
|
113
|
|
1,979
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interests
|
365
|
|
|
|
|
|
|
|
(32)
|
|
|
|
|
|
333
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to shareholders
|
1,802
|
|
157
|
|
2
|
|
45
|
|
326
|
|
(799)
|
|
113
|
|
1,646
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
35.9p
|
|
3.1p
|
|
-
|
|
0.9p
|
|
6.5p
|
|
(15.9)p
|
|
2.3p
|
|
32.8p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares
(millions)
|
5,020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three months ended 31 March 2021
|
|
|
Total
results
£m
|
|
Intangible
amort-
isation
£m
|
|
Intangible
impair-
ment
£m
|
|
Major
restruct-
uring
£m
|
|
Trans-
action-
related
£m
|
|
Divest-
ments,
significant
legal
and
other
items
£m
|
|
Sepa-
ration
costs
£m
|
|
Adjusted
results
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
7,418
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,418
|
|
Cost of
sales
|
(2,480)
|
|
175
|
|
1
|
|
34
|
|
7
|
|
27
|
|
|
|
(2,236)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
4,938
|
|
175
|
|
1
|
|
34
|
|
7
|
|
27
|
|
|
|
5,182
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,427)
|
|
|
|
|
|
75
|
|
|
|
2
|
|
35
|
|
(2,315)
|
|
Research
and development
|
(1,118)
|
|
26
|
|
13
|
|
2
|
|
|
|
|
|
|
|
(1,077)
|
|
Royalty
income
|
91
|
|
|
|
|
|
|
|
|
|
|
|
|
|
91
|
|
Other
operating income/(expense)
|
209
|
|
|
|
|
|
(1)
|
|
109
|
|
(317)
|
|
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit
|
1,693
|
|
201
|
|
14
|
|
110
|
|
116
|
|
(288)
|
|
35
|
|
1,881
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
finance cost
|
(191)
|
|
|
|
|
|
1
|
|
|
|
|
|
|
|
(190)
|
|
Share
of after tax profits of
associates
and joint ventures
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation
|
1,518
|
|
201
|
|
14
|
|
111
|
|
116
|
|
(288)
|
|
35
|
|
1,707
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation
|
(258)
|
|
(39)
|
|
(3)
|
|
(24)
|
|
(31)
|
|
44
|
|
(7)
|
|
(318)
|
|
Tax rate %
|
17.0%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18.6%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after taxation
|
1,260
|
|
162
|
|
11
|
|
87
|
|
85
|
|
(244)
|
|
28
|
|
1,389
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
attributable to non-controlling
interests
|
187
|
|
|
|
|
|
|
|
59
|
|
|
|
|
|
246
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit attributable to shareholders
|
1,073
|
|
162
|
|
11
|
|
87
|
|
26
|
|
(244)
|
|
28
|
|
1,143
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per share
|
21.5p
|
|
3.2p
|
|
0.2p
|
|
1.7p
|
|
0.5p
|
|
(4.8)p
|
|
0.6p
|
|
22.9p
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted
average number of shares
(millions)
|
4,993
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,993
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Major restructuring and integration
|
|
Total
Major restructuring charges incurred in Q1 2022 were £59
million (Q1 2021: £110 million), analysed as
follows:
|
|
|
Q1 2022
|
|
Q1
2021
|
||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
Cash
£m
|
|
Non-
cash
£m
|
|
Total
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Separation
Preparation restructuring
programme
|
13
|
|
38
|
|
51
|
|
79
|
|
9
|
|
88
|
|
Consumer
Healthcare Joint Venture
integration
programme
|
2
|
|
4
|
|
6
|
|
40
|
|
4
|
|
44
|
|
Legacy
programmes
|
1
|
|
1
|
|
2
|
|
7
|
|
(29)
|
|
(22)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16
|
|
43
|
|
59
|
|
126
|
|
(16)
|
|
110
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash
charges of £13 million under the Separation Preparation
programme primarily arose from the restructuring of some
administrative functions as well as commercial pharmaceuticals and
R&D functions. The non-cash charges of £38 million
primarily reflected the write-down of assets in administrative
locations and R&D sites.
Total
cash payments made in Q1 2022 were £171 million (Q1 2021:
£211 million), £120 million (Q1 2021: £100
million) relating to the Separation Preparation restructuring
programme, a further £31 million (Q1 2021: £60 million)
relating to the Consumer Healthcare Joint Venture integration
programme and £20 million (Q1 2021: £51 million) relating
to other legacy programmes including the settlement of certain
charges accrued in previous quarters.
|
|
The
analysis of Major restructuring charges by Income statement line
was as follows:
|
|
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
|
|
|
|
|
Cost of
sales
|
16
|
|
34
|
|
Selling,
general and administration
|
37
|
|
75
|
|
Research
and development
|
6
|
|
2
|
|
Other
operating income
|
-
|
|
(1)
|
|
|
|
|
|
|
Total
Major restructuring costs
|
59
|
|
110
|
|
|
|
|
|
|
The
benefit in the quarter from restructuring programmes was £0.1
billion, primarily relating to the Separation Preparation
restructuring programme.
The
Group initiated in Q1 2020 a two-year Separation Preparation
programme to prepare for the separation of GSK into two companies:
new GSK, a biopharma company with an R&D approach focused on
science related to the immune system, the use of human genetics and
new technologies, and a new leader in Consumer Healthcare. The
programme aims to:
|
|
●
|
Drive a
common approach to R&D with improved capital
allocation
|
|
●
|
Align
and improve the capabilities and efficiency of global support
functions to support new GSK
|
|
●
|
Further
optimise the supply chain and product portfolio, including the
divestment of non-core assets
|
|
●
|
Prepare
Consumer Healthcare to operate as a standalone company
|
|
The
programme continues to target delivery of £0.8 billion of
annual savings by 2022 and £1.0 billion by 2023, with total
costs estimated at £2.4 billion, of which £1.6 billion is
expected to be cash costs. The proceeds of divestments have largely
covered the cash costs of the programme.
|
|
The
completion of the Consumer Healthcare Joint Venture with Pfizer has
realised substantial cost synergies and largely delivered the
expected total annual cost savings of £0.5 billion by 2021. In
February 2022, at the Haleon Capital Markets Day, the projected
savings from this programme were announced as increased by
£0.1 billion to £0.6 billion by 2022. The cash costs are
expected to be £0.7 billion and non-cash charges are expected
to be £0.1 billion, plus an additional capital expenditure of
£0.2 billion. Up to 25% of the cost savings are intended to be
reinvested in the business to support innovation and other growth
opportunities.
|
|
Transaction-related adjustments
Transaction-related
adjustments resulted in a net charge of £347 million (Q1 2021:
£116 million). This included a net £332 million
accounting charge for the re-measurement of contingent
consideration liabilities and the liabilities for the Pfizer put
option and Pfizer and Shionogi preferential dividends in ViiV
Healthcare.
|
|
Charge/(credit)
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
|
|
|
|
|
Contingent
consideration on former Shionogi-ViiV Healthcare joint
Venture
(including
Shionogi preferential dividends)
|
256
|
|
134
|
|
ViiV
Healthcare put options and Pfizer preferential
dividends
|
32
|
|
(53)
|
|
Contingent
consideration on former Novartis Vaccines business
|
44
|
|
26
|
|
Other
adjustments
|
15
|
|
9
|
|
|
|
|
|
|
Total
transaction-related charges
|
347
|
|
116
|
|
|
|
|
|
|
The £256 million charge relating to the contingent
consideration for the former Shionogi-ViiV Healthcare joint venture
represented an increase in the valuation of the contingent
consideration due to Shionogi, as a result of the unwind of the
discount for £101 million and a charge of £155 million
primarily from exchange rates as well as adjustments to sales
forecasts. The £32 million charge relating to the ViiV
Healthcare put option and Pfizer preferential dividends represented
an increase in the valuation of the put option primarily as a
result of updated exchange rates and adjustments to sales
forecasts.
The
ViiV Healthcare contingent consideration liability is fair valued
under IFRS. An explanation of the accounting for the
non-controlling interests in ViiV Healthcare is set out on page
21.
Divestments, significant legal charges, and other
items
Divestments,
significant legal charges and other items primarily included the
£924 million upfront settlement income received from Gilead,
as well as gains from a number of asset disposals, fair value gains
on investments and certain other Adjusting items.
Separation costs
From Q2
2020, the Group started to report additional costs to prepare for
establishment of the Consumer Healthcare business as an independent
entity (“Separation costs”). Total separation costs
incurred in Q1 2022 were £139 million (Q1 2021: £35
million). This includes £22 million relating to transaction
costs incurred in connection with the demerger and preparatory
admission costs related to the listing of Consumer
Healthcare.
Total separation costs are estimated to be £600-700 million,
excluding transaction costs.
|
|
Cash generation
|
|
Cash flow
|
|
|
Q1 2022
|
|
Q1
2021
|
|
|
|
|
|
|
Cash
generated from operations (£m)
|
2,755
|
|
486
|
|
Net
cash inflow from operating activities (£m)
|
2,542
|
|
331
|
|
Free
cash flow* (£m)
|
1,650
|
|
(3)
|
|
Free
cash flow growth (%)
|
>100%
|
|
>(100)%
|
|
Free
cash flow conversion* (%)
|
92%
|
|
<-%
|
|
Net
debt** (£m)
|
19,351
|
|
21,402
|
|
*
|
Free
cash flow and free cash flow conversion are defined on page
42.
|
|
**
|
Net
debt is analysed on page 33.
|
|
Q1 2022
Cash generated from operating activities for the quarter was
£2,755 million (Q1 2021: £486 million). The increase
primarily reflected a significant increase in operating profit
including the upfront income from the settlement with Gilead,
favourable timing of collections and profit share payments
for Xevudy sales and a lower seasonal increase in
inventory.
Total cash payments to Shionogi in relation to the ViiV Healthcare
contingent consideration liability in the quarter were £208
million (Q1 2021: £216 million), of which £183 million
was recognised in cash flows from operating activities and £25
million was recognised in contingent consideration paid within
investing cash flows. These payments are deductible for tax
purposes.
Free
cash inflow was £1,650 million for the quarter (Q1 2021:
£3 million outflow). The increase primarily reflected the
significant increase in operating profit including the upfront
income from the settlement with Gilead, favourable timing of
collections and profit share payments for Xevudy sales and lower seasonal
increase in inventory. This was partially offset by lower proceeds
from disposals and higher purchases of intangible asset, as well as
higher tax payments and capital expenditure.
|
|
Net debt
At 31
March 2022, net debt was £19.4 billion, compared with
£19.8 billion at 31 December 2021, comprising gross debt of
£33.3 billion which increased primarily due to the debt
issuance for Consumer Healthcare, cash and liquid investments of
£11.0 billion and cash advances and a short-term loan to a
subsidiary of Pfizer Inc. of £2.9 billion, reflecting an
on-lend of a portion of the cash received from the proceeds of the
Consumer Healthcare bond issuance in line with Pfizer’s
shareholding of the Consumer Healthcare Joint Venture. Net debt
reduced due to £1.7 billion free cash flow partly offset by
the dividends paid to shareholders of £1.0 billion, £0.2
billion of net adverse exchange impacts from the translation of
non-Sterling denominated debt and exchange on other financing items
and additional investments of £0.1 billion.
At 31
March 2022, GSK had short-term borrowings (including overdrafts and
lease liabilities) repayable within 12 months of £4.1 billion
with loans of £3.9 billion repayable in the subsequent
year.
|
|
Returns to shareholders
|
|
Quarterly dividends
The
Board has declared a first interim dividend for 2022 of 14 pence
per share (Q1 2021: 19 pence per share).
As set
out at the new GSK Investor Update in June 2021, from 2022 GSK will
adopt a progressive dividend policy targeting a dividend pay-out
ratio equivalent to 40 to 60% over the investment cycle. The
dividend policy, the total expected cash distribution, and the
respective dividend pay-out ratios for new GSK and new Consumer
Healthcare remain unchanged.
GSK
expects to declare a 27p per share dividend payable by the current
group for the first half. This comprises 22p per share for new GSK
and 5p per share representing Consumer Healthcare during the first
half whilst part of the group. For the second half of 2022, new GSK
continues to expect to declare a 22p per share dividend. As
previously communicated, new GSK would expect to declare a dividend
of 45p per share for 2023.
Following separation, the dividend policy for the new Consumer
Healthcare company will be the responsibility of its Board of
Directors and is expected to be guided by a 30 to 50 per cent
pay-out ratio. We expect a second-half dividend from the new
Consumer Healthcare company equivalent to a pay-out of around 3p
per share, subject to its Board’s decisions on the intra-year
phasing of dividend payments.
In
aggregate, this would represent on the full year 2022 basis the
equivalent of a Group dividend of around 52p per share. Dividends
payable by Consumer Healthcare will only be receivable by
shareholders who remain invested in Consumer Healthcare
post-separation and at the appropriate record dates.
Payment of dividends
The
equivalent interim dividend receivable by ADR holders will be
calculated based on the exchange rate on 29 June 2022. An annual
fee of $0.03 per ADS (or $0.0075 per ADS per quarter) is charged by
the Depositary.
The
ex-dividend date will be 19 May 2022, with a record date of 20 May
2022 and a payment date of 1 July 2022.
|
|
|
Paid/
payable
|
|
Pence
per
share
|
|
£m
|
|
|
|
|
|
|
|
|
2022
|
|
|
|
|
|
|
First
interim
|
1 July
2022
|
|
14
|
|
704
|
|
2021
|
|
|
|
|
|
|
First
interim
|
8 July
2021
|
|
19
|
|
951
|
|
Second
interim
|
7
October 2021
|
|
19
|
|
951
|
|
Third
interim
|
13
January 2022
|
|
19
|
|
952
|
|
Fourth
interim
|
7 April
2022
|
|
23
|
|
1,157
|
|
|
|
|
|
|
|
|
|
|
|
80
|
|
4,011
|
|
|
|
|
|
|
|
|
Weighted average number of shares
|
|||||
|
|
|
|
Q1 2022
millions
|
|
Q1
2021
millions
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – basic
|
|
|
5,020
|
|
4,993
|
|
Dilutive
effect of share options and share awards
|
|
|
48
|
|
44
|
|
|
|
|
|
|
|
|
Weighted
average number of shares – diluted
|
|
|
5,068
|
|
5,037
|
|
|
|
|
|
|
|
|
At 31
March 2022, 5,030 million shares (Q1 2021: 5,003 million) were in
free issue (excluding Treasury shares and shares held by the ESOP
Trusts). GSK made no share repurchases during the period. The
company issued 1.8 million shares under employee share schemes in
the period for proceeds of £17 million (Q1 2021: £15
million).
|
|
At 31
March 2022 , the ESOP Trust held 53.2 million GSK shares against
the future exercise of share options and share awards. The carrying
value of £403 million has been deducted from other reserves.
The market value of these shares was £882
million.
At 31
March 2022, the company held 304.9 million Treasury shares at a
cost of £4,265 million, which has been deducted from retained
earnings.
|
|
Total and Adjusted
results
|
|
Total
reported results represent the Group’s overall
performance.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined below and other non-IFRS measures are
defined on page 42.
GSK
believes that Adjusted results, when considered together with Total
results, provide investors, analysts and other stakeholders with
helpful complementary information to understand better the
financial performance and position of the Group from period to
period, and allow the Group’s performance to be more easily
compared against the majority of its peer companies. These measures
are also used by management for planning and reporting purposes.
They may not be directly comparable with similarly described
measures used by other companies.
GSK
encourages investors and analysts not to rely on any single
financial measure but to review GSK’s quarterly results
announcements, including the financial statements and notes, in
their entirety.
GSK is
committed to continuously improving its financial reporting, in
line with evolving regulatory requirements and best practice. In
line with this practice, GSK expects to continue to review and
refine its reporting framework.
Adjusted
results exclude the following items from Total results, together
with the tax effects of all of these items:
|
|
●
|
amortisation
of intangible assets (excluding computer software and capitalised
development costs)
|
|
●
|
impairment
of intangible assets (excluding computer software) and
goodwill
|
|
●
|
Major
restructuring costs, which include impairments of tangible assets
and computer software, (under specific Board approved programmes
that are structural, of a significant scale and where the costs of
individual or related projects exceed £25 million), including
integration costs following material acquisitions
|
|
●
|
transaction-related
accounting or other adjustments related to significant
acquisitions
|
|
●
|
proceeds
and costs of disposal of associates, products and businesses;
significant settlement income; significant legal charges (net of
insurance recoveries) and expenses on the settlement of litigation
and government investigations; other operating income other than
royalty income, and other items
|
|
●
|
separation
costs include costs to establish Consumer Healthcare as an
independent business, as well as admission listing and demerger
costs
|
|
Costs
for all other ordinary course smaller scale restructuring and legal
charges and expenses are retained within both Total and Adjusted
results.
As
Adjusted results include the benefits of Major restructuring
programmes but exclude significant costs (such as significant
legal, major restructuring and transaction items) they should not
be regarded as a complete picture of the Group’s financial
performance, which is presented in Total results. The exclusion of
other Adjusting items may result in Adjusted earnings being
materially higher or lower than Total earnings. In particular, when
significant impairments, restructuring charges and legal costs are
excluded, Adjusted earnings will be higher than Total
earnings.
GSK has
undertaken a number of Major restructuring programmes in response
to significant changes in the Group’s trading environment or
overall strategy, or following material acquisitions. Within the
Pharmaceuticals sector, the highly regulated manufacturing
operations and supply chains and long lifecycle of the business
mean that restructuring programmes, particularly those that involve
the rationalisation or closure of manufacturing or R&D sites
are likely to take several years to complete. Costs, both cash and
non-cash, of these programmes are provided for as individual
elements are approved and meet the accounting recognition criteria.
As a result, charges may be incurred over a number of years
following the initiation of a Major restructuring
programme.
Significant
legal charges and expenses are those arising from the settlement of
litigation or government investigations that are not in the normal
course and materially larger than more regularly occurring
individual matters. They also include certain major legacy
matters.
Reconciliations
between Total and Adjusted results, providing further information
on the key Adjusting items, are set out on page 15.
GSK
provides earnings guidance to the investor community on the basis
of Adjusted results. This is in line with peer companies and
expectations of the investor community, supporting easier
comparison of the Group’s performance with its peers. GSK is
not able to give guidance for Total results as it cannot reliably
forecast certain material elements of the Total results,
particularly the future fair value movements on contingent
consideration and put options that can and have given rise to
significant adjustments driven by external factors such as currency
and other movements in capital markets.
|
|
ViiV Healthcare
ViiV
Healthcare is a subsidiary of the Group and 100% of its operating
results (turnover, operating profit, profit after tax) are included
within the Group income statement.
Earnings
are allocated to the three shareholders of ViiV Healthcare on the
basis of their respective equity shareholdings (GSK 78.3%, Pfizer
11.7% and Shionogi 10%) and their entitlement to preferential
dividends, which are determined by the performance of certain
products that each shareholder contributed. As the relative
performance of these products changes over time, the proportion of
the overall earnings allocated to each shareholder also changes. In
particular, the increasing proportion of sales of dolutegravir and
cabotegravir-containing products has a favourable impact on the
proportion of the preferential dividends that is allocated to GSK.
Adjusting items are allocated to shareholders based on their equity
interests. GSK was entitled to approximately 86% of the Total
earnings and 83% of the Adjusted earnings of ViiV Healthcare for
2021.
As
consideration for the acquisition of Shionogi’s interest in
the former Shionogi-ViiV Healthcare joint venture in 2012, Shionogi
received the 10% equity stake in ViiV Healthcare and ViiV
Healthcare also agreed to pay additional future cash consideration
to Shionogi, contingent on the future sales performance of the
products being developed by that joint venture, dolutegravir and
cabotegravir. Under IFRS 3 ‘Business combinations’, GSK
was required to provide for the estimated fair value of this
contingent consideration at the time of acquisition and is required
to update the liability to the latest estimate of fair value at
each subsequent period end. The liability for the contingent
consideration recognised in the balance sheet at the date of
acquisition was £659 million. Subsequent re-measurements are
reflected within other operating income/(expense) and within
Adjusting items in the income statement in each
period.
On 1
February 2022, ViiV Healthcare reached agreement with Gilead to
settle the global patent infringement litigation relating to the
commercialisation of Gilead’s Biktarvy. Under the terms of the global settlement and
licensing agreement, Gilead made an upfront payment of $1.25
billion to ViiV Healthcare in February
2022. In addition, Gilead will also pay a 3% royalty on all future
US sales of Biktarvy and in respect of the bictegravir component of
any other future bictegravir-containing products sold in the US.
These royalties will be payable by Gilead to ViiV Healthcare from 1
February 2022 until the expiry of ViiV Healthcare's US
Patent No. 8,129,385 on 5 October
2027. Gilead's obligation to pay royalties does not extend into any
period of regulatory paediatric exclusivity, if
awarded.
Cash
payments to settle the contingent consideration are made to
Shionogi by ViiV Healthcare each quarter, based on the actual sales
performance and other income of the relevant products in the
previous quarter. These payments reduce the balance sheet liability
and hence are not recorded in the income statement. The cash
payments made to Shionogi by ViiV Healthcare in Q1 2022 were
£208 million.
As the
liability is required to be recorded at the fair value of estimated
future payments, there is a significant timing difference between
the charges that are recorded in the Total income statement to
reflect movements in the fair value of the liability and the actual
cash payments made to settle the liability.
Further
explanation of the acquisition-related arrangements with ViiV
Healthcare are set out on pages 57 and 58 of the Annual Report
2021.
|
|
Financial information
|
|
Income statements
|
|
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
|
|
|
|
|
TURNOVER
|
9,780
|
|
7,418
|
|
|
|
|
|
|
Cost of
sales
|
(3,690)
|
|
(2,480)
|
|
|
|
|
|
|
Gross
profit
|
6,090
|
|
4,938
|
|
|
|
|
|
|
Selling,
general and administration
|
(2,844)
|
|
(2,427)
|
|
Research
and development
|
(1,167)
|
|
(1,118)
|
|
Royalty income
|
139
|
|
91
|
|
Other
operating income
|
583
|
|
209
|
|
|
|
|
|
|
OPERATING PROFIT
|
2,801
|
|
1,693
|
|
|
|
|
|
|
Finance
income
|
10
|
|
10
|
|
Finance
expense
|
(212)
|
|
(201)
|
|
Share
of after tax (losses)/profits of associates and joint
ventures
|
(1)
|
|
16
|
|
|
|
|
|
|
PROFIT BEFORE TAXATION
|
2,598
|
|
1,518
|
|
|
|
|
|
|
Taxation
|
(431)
|
|
(258)
|
|
Tax rate %
|
16.6%
|
|
17.0%
|
|
|
|
|
|
|
PROFIT AFTER TAXATION
|
2,167
|
|
1,260
|
|
|
|
|
|
|
Profit
attributable to non-controlling interests
|
365
|
|
187
|
|
Profit
attributable to shareholders
|
1,802
|
|
1,073
|
|
|
|
|
|
|
|
2,167
|
|
1,260
|
|
|
|
|
|
|
EARNINGS PER SHARE
|
35.9p
|
|
21.5p
|
|
|
|
|
|
|
Diluted
earnings per share
|
35.6p
|
|
21.3p
|
|
|
|
|
|
|
Statement of comprehensive income
|
|
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
|
|
|
|
|
Profit
for the period
|
2,167
|
|
1,260
|
|
|
|
|
|
|
Items that may be reclassified subsequently to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets and net investment
hedges
|
267
|
|
(267)
|
|
Reclassification
of exchange movements on liquidation or disposal of
overseas
subsidiaries and associates
|
|
|
|
|
Fair
value movements on cash flow hedges
|
194
|
|
(11)
|
|
Reclassification
of cash flow hedges to income statement
|
(1)
|
|
14
|
|
Deferred
tax on fair value movements on cash flow hedges
|
(44)
|
|
-
|
|
|
|
|
|
|
|
416
|
|
(264)
|
|
|
|
|
|
|
Items that will not be reclassified to income
statement:
|
|
|
|
|
Exchange
movements on overseas net assets of non-controlling
interests
|
4
|
|
(34)
|
|
Fair
value movements on equity investments
|
(543)
|
|
236
|
|
Tax on
fair value movements on equity investments
|
47
|
|
54
|
|
Re-measurement
gains on defined benefit plans
|
313
|
|
23
|
|
Tax on
re-measurement losses on defined benefit plans
|
(73)
|
|
(12)
|
|
|
|
|
|
|
|
(252)
|
|
267
|
|
|
|
|
|
|
Other
comprehensive income for the period
|
164
|
|
3
|
|
|
|
|
|
|
Total
comprehensive income for the period
|
2,331
|
|
1,263
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the period attributable to:
|
|
|
|
|
Shareholders
|
1,962
|
|
1,110
|
|
Non-controlling
interests
|
369
|
|
153
|
|
|
|
|
|
|
|
2,331
|
|
1,263
|
|
|
|
|
|
|
Specialty Medicines turnover –
three months ended 31 March 2022
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,181
|
|
15
|
|
14
|
|
697
|
|
17
|
|
13
|
|
299
|
|
4
|
|
8
|
|
185
|
|
26
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dolutegravir
products
|
1,102
|
|
11
|
|
11
|
|
641
|
|
11
|
|
8
|
|
287
|
|
3
|
|
6
|
|
174
|
|
30
|
|
34
|
|
Tivicay
|
320
|
|
6
|
|
7
|
|
160
|
|
(2)
|
|
(5)
|
|
65
|
|
(13)
|
|
(11)
|
|
95
|
|
51
|
|
57
|
|
Triumeq
|
392
|
|
(10)
|
|
(11)
|
|
245
|
|
(4)
|
|
(7)
|
|
94
|
|
(22)
|
|
(20)
|
|
53
|
|
(10)
|
|
(8)
|
|
Juluca
|
133
|
|
19
|
|
18
|
|
99
|
|
19
|
|
16
|
|
30
|
|
15
|
|
23
|
|
4
|
|
33
|
|
33
|
|
Dovato
|
257
|
|
82
|
|
82
|
|
137
|
|
85
|
|
78
|
|
98
|
|
69
|
|
76
|
|
22
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rukobia
|
16
|
|
>100
|
|
>100
|
|
15
|
|
>100
|
|
>100
|
|
1
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
Cabenuva
|
38
|
|
>100
|
|
>100
|
|
32
|
|
>100
|
|
>100
|
|
6
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
Apretude
|
2
|
|
-
|
|
-
|
|
2
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
Other
|
23
|
|
(28)
|
|
(19)
|
|
7
|
|
(42)
|
|
(33)
|
|
5
|
|
(29)
|
|
(14)
|
|
11
|
|
(15)
|
|
(8)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
127
|
|
15
|
|
15
|
|
69
|
|
6
|
|
3
|
|
54
|
|
26
|
|
30
|
|
4
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Zejula
|
98
|
|
11
|
|
11
|
|
51
|
|
-
|
|
(4)
|
|
43
|
|
19
|
|
22
|
|
4
|
|
>100
|
|
>100
|
|
Blenrep
|
25
|
|
19
|
|
19
|
|
16
|
|
14
|
|
14
|
|
9
|
|
29
|
|
29
|
|
-
|
|
-
|
|
-
|
|
Jemperli
|
4
|
|
>100
|
|
>100
|
|
2
|
|
-
|
|
-
|
|
2
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-
inflammation,
respiratory and other
|
520
|
|
18
|
|
18
|
|
347
|
|
18
|
|
14
|
|
84
|
|
8
|
|
13
|
|
89
|
|
35
|
|
38
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Benlysta
|
215
|
|
21
|
|
18
|
|
170
|
|
17
|
|
14
|
|
19
|
|
19
|
|
19
|
|
26
|
|
53
|
|
53
|
|
Nucala
|
295
|
|
16
|
|
16
|
|
177
|
|
18
|
|
15
|
|
65
|
|
5
|
|
10
|
|
53
|
|
26
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic
|
1,307
|
|
-
|
|
-
|
|
770
|
|
-
|
|
-
|
|
311
|
|
-
|
|
-
|
|
226
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Xevudy
|
1,307
|
|
-
|
|
-
|
|
770
|
|
-
|
|
-
|
|
311
|
|
-
|
|
-
|
|
226
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Specialty Medicines
|
3,135
|
|
98
|
|
97
|
|
1,883
|
|
97
|
|
91
|
|
748
|
|
83
|
|
88
|
|
504
|
|
>100
|
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines turnover – three
months ended 31 March 2022
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Meningitis
|
212
|
|
12
|
|
12
|
|
99
|
|
80
|
|
75
|
|
83
|
|
(8)
|
|
(6)
|
|
30
|
|
(33)
|
|
(29)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Bexsero
|
163
|
|
22
|
|
23
|
|
66
|
|
>100
|
|
>100
|
|
79
|
|
(7)
|
|
(5)
|
|
18
|
|
-
|
|
11
|
|
Menveo
|
42
|
|
8
|
|
5
|
|
33
|
|
37
|
|
33
|
|
3
|
|
(25)
|
|
(25)
|
|
6
|
|
(45)
|
|
(45)
|
|
Other
|
7
|
|
(59)
|
|
(59)
|
|
-
|
|
-
|
|
-
|
|
1
|
|
-
|
|
-
|
|
6
|
|
(63)
|
|
(63)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Influenza
|
18
|
|
-
|
|
-
|
|
1
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
17
|
|
(6)
|
|
(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fluarix, FluLaval
|
18
|
|
-
|
|
-
|
|
1
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
17
|
|
(6)
|
|
(6)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingles
|
698
|
|
>100
|
|
>100
|
|
490
|
|
82
|
|
77
|
|
160
|
|
>100
|
|
>100
|
|
48
|
|
78
|
|
70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shingrix
|
698
|
|
>100
|
|
>100
|
|
490
|
|
82
|
|
77
|
|
160
|
|
>100
|
|
>100
|
|
48
|
|
78
|
|
70
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Vaccines
|
741
|
|
8
|
|
8
|
|
302
|
|
67
|
|
61
|
|
166
|
|
(11)
|
|
(8)
|
|
273
|
|
(15)
|
|
(14)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Infanrix, Pediarix
|
175
|
|
29
|
|
27
|
|
112
|
|
75
|
|
70
|
|
29
|
|
(27)
|
|
(25)
|
|
34
|
|
6
|
|
6
|
|
Boostrix
|
126
|
|
34
|
|
33
|
|
70
|
|
63
|
|
58
|
|
33
|
|
(8)
|
|
(6)
|
|
23
|
|
53
|
|
53
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hepatitis
|
122
|
|
28
|
|
27
|
|
78
|
|
53
|
|
47
|
|
29
|
|
21
|
|
25
|
|
15
|
|
(25)
|
|
(20)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Rotarix
|
117
|
|
3
|
|
5
|
|
35
|
|
59
|
|
55
|
|
32
|
|
7
|
|
10
|
|
50
|
|
(19)
|
|
(15)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Synflorix
|
81
|
|
(21)
|
|
(19)
|
|
-
|
|
-
|
|
-
|
|
6
|
|
(50)
|
|
(42)
|
|
75
|
|
(17)
|
|
(16)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Priorix, Priorix
Tetra, Varilrix
|
47
|
|
(25)
|
|
(25)
|
|
-
|
|
-
|
|
-
|
|
28
|
|
(12)
|
|
(9)
|
|
19
|
|
(39)
|
|
(42)
|
|
Cervarix
|
29
|
|
(36)
|
|
(38)
|
|
-
|
|
-
|
|
-
|
|
4
|
|
(50)
|
|
(50)
|
|
25
|
|
(32)
|
|
(35)
|
|
Other
|
44
|
|
10
|
|
13
|
|
7
|
|
>100
|
|
>100
|
|
5
|
|
25
|
|
25
|
|
32
|
|
(9)
|
|
(3)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pandemic vaccines
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
Pandemic
adjuvant
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vaccines
|
1,669
|
|
36
|
|
36
|
|
892
|
|
77
|
|
71
|
|
409
|
|
33
|
|
38
|
|
368
|
|
(11)
|
|
(9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Medicines turnover –
three months ended 31 March 2022
|
|
|
Total
|
|
US
|
|
Europe
|
|
International
|
||||||||||||||||
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
|
|
|
Growth
|
||||||||
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
£m
|
|
£%
|
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Respiratory
|
1,535
|
|
3
|
|
3
|
|
722
|
|
6
|
|
3
|
|
333
|
|
(2)
|
|
1
|
|
480
|
|
1
|
|
4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arnuity Ellipta
|
13
|
|
>100
|
|
>100
|
|
11
|
|
>100
|
|
>100
|
|
-
|
|
-
|
|
-
|
|
2
|
|
-
|
|
-
|
|
Anoro Ellipta
|
98
|
|
(16)
|
|
(15)
|
|
41
|
|
(35)
|
|
(37)
|
|
38
|
|
6
|
|
8
|
|
19
|
|
6
|
|
11
|
|
Avamys/Veramyst
|
94
|
|
(9)
|
|
(5)
|
|
-
|
|
-
|
|
-
|
|
16
|
|
-
|
|
6
|
|
78
|
|
(10)
|
|
(7)
|
|
Flixotide/Flovent
|
127
|
|
9
|
|
8
|
|
85
|
|
21
|
|
17
|
|
18
|
|
12
|
|
12
|
|
24
|
|
(23)
|
|
(16)
|
|
Incruse Ellipta
|
50
|
|
(4)
|
|
(6)
|
|
26
|
|
(4)
|
|
(4)
|
|
16
|
|
(11)
|
|
(6)
|
|
8
|
|
14
|
|
(14)
|
|
Relvar/Breo Ellipta
|
275
|
|
3
|
|
3
|
|
120
|
|
7
|
|
4
|
|
83
|
|
1
|
|
5
|
|
72
|
|
(3)
|
|
-
|
|
Seretide/Advair
|
302
|
|
(14)
|
|
(14)
|
|
84
|
|
(28)
|
|
(30)
|
|
73
|
|
(23)
|
|
(21)
|
|
145
|
|
4
|
|
5
|
|
Trelegy Ellipta
|
340
|
|
37
|
|
35
|
|
238
|
|
38
|
|
34
|
|
53
|
|
18
|
|
20
|
|
49
|
|
63
|
|
70
|
|
Ventolin
|
201
|
|
6
|
|
6
|
|
117
|
|
4
|
|
1
|
|
30
|
|
20
|
|
24
|
|
54
|
|
4
|
|
10
|
|
Other
Respiratory
|
35
|
|
(15)
|
|
(10)
|
|
-
|
|
-
|
|
-
|
|
6
|
|
-
|
|
17
|
|
29
|
|
(17)
|
|
(11)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other General Medicines
|
808
|
|
-
|
|
3
|
|
89
|
|
14
|
|
12
|
|
170
|
|
(16)
|
|
(13)
|
|
549
|
|
4
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
92
|
|
(8)
|
|
(5)
|
|
-
|
|
-
|
|
-
|
|
27
|
|
(21)
|
|
(18)
|
|
65
|
|
(2)
|
|
2
|
|
Augmentin
|
129
|
|
42
|
|
51
|
|
-
|
|
-
|
|
-
|
|
36
|
|
57
|
|
65
|
|
93
|
|
37
|
|
46
|
|
Avodart
|
81
|
|
(2)
|
|
(1)
|
|
-
|
|
-
|
|
-
|
|
27
|
|
(10)
|
|
(10)
|
|
54
|
|
4
|
|
6
|
|
Lamictal
|
120
|
|
3
|
|
3
|
|
59
|
|
7
|
|
4
|
|
26
|
|
(7)
|
|
(4)
|
|
35
|
|
6
|
|
9
|
|
Other
|
386
|
|
(8)
|
|
(5)
|
|
30
|
|
36
|
|
36
|
|
54
|
|
(39)
|
|
(36)
|
|
302
|
|
(3)
|
|
1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
General Medicines
|
2,343
|
|
2
|
|
3
|
|
811
|
|
7
|
|
4
|
|
503
|
|
(7)
|
|
(4)
|
|
1,029
|
|
2
|
|
6
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial Operations turnover
– three months ended 31 March 2022
|
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
7,147
|
40
|
40
|
3,586
|
62
|
57
|
1,660
|
32
|
36
|
1,901
|
17
|
20
|
|
Balance sheet
|
|
|
|
|
31 March 2022
£m
|
|
31
December 2021
£m
|
|
ASSETS
|
|
|
|
|
|
|
Non-current assets
|
|
|
|
|
|
|
Property,
plant and equipment
|
|
|
9,964
|
|
9,932
|
|
Right
of use assets
|
|
|
740
|
|
740
|
|
Goodwill
|
|
|
10,705
|
|
10,552
|
|
Other
intangible assets
|
|
|
30,468
|
|
30,079
|
|
Investments
in associates and joint ventures
|
|
|
83
|
|
88
|
|
Other
investments
|
|
|
1,656
|
|
2,126
|
|
Deferred
tax assets
|
|
|
5,263
|
|
5,218
|
|
Derivative
financial instruments
|
|
|
16
|
|
18
|
|
Other
non-current assets
|
|
|
1,806
|
|
1,676
|
|
|
|
|
|
|
|
|
Total non-current assets
|
|
|
60,701
|
|
60,429
|
|
|
|
|
|
|
|
|
Current assets
|
|
|
|
|
|
|
Inventories
|
|
|
6,003
|
|
5,783
|
|
Current
tax recoverable
|
|
|
497
|
|
486
|
|
Trade
and other receivables
|
|
|
8,300
|
|
7,860
|
|
Derivative
financial instruments
|
|
|
176
|
|
188
|
|
Liquid
investments and short term loans to third parties
|
|
|
3,010
|
|
61
|
|
Cash
and cash equivalents
|
|
|
10,967
|
|
4,274
|
|
Assets
held for sale
|
|
|
35
|
|
22
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
28,988
|
|
18,674
|
|
|
|
|
|
|
|
|
TOTAL ASSETS
|
|
|
89,689
|
|
79,103
|
|
|
|
|
|
|
|
|
LIABILITIES
|
|
|
|
|
|
|
Current liabilities
|
|
|
|
|
|
|
Short-term
borrowings
|
|
|
(4,102)
|
|
(3,601)
|
|
Contingent
consideration liabilities
|
|
|
(971)
|
|
(958)
|
|
Trade
and other payables
|
|
|
(17,577)
|
|
(17,554)
|
|
Derivative
financial instruments
|
|
|
(152)
|
|
(227)
|
|
Current
tax payable
|
|
|
(783)
|
|
(489)
|
|
Short-term
provisions
|
|
|
(693)
|
|
(841)
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
(24,278)
|
|
(23,670)
|
|
|
|
|
|
|
|
|
Non-current liabilities
|
|
|
|
|
|
|
Long-term
borrowings
|
|
|
(29,226)
|
|
(20,572)
|
|
Corporation
tax payable
|
|
|
(184)
|
|
(180)
|
|
Deferred
tax liabilities
|
|
|
(3,668)
|
|
(3,556)
|
|
Pensions
and other post-employment benefits
|
|
|
(2,940)
|
|
(3,113)
|
|
Other
provisions
|
|
|
(643)
|
|
(630)
|
|
Derivative
financial instruments
|
|
|
(23)
|
|
(1)
|
|
Contingent
consideration liabilities
|
|
|
(5,198)
|
|
(5,118)
|
|
Other
non-current liabilities
|
|
|
(897)
|
|
(921)
|
|
|
|
|
|
|
|
|
Total non-current liabilities
|
|
|
(42,779)
|
|
(34,091)
|
|
|
|
|
|
|
|
|
TOTAL LIABILITIES
|
|
|
(67,057)
|
|
(57,761)
|
|
|
|
|
|
|
|
|
NET ASSETS
|
|
|
22,632
|
|
21,342
|
|
|
|
|
|
|
|
|
EQUITY
|
|
|
|
|
|
|
Share
capital
|
|
|
1,347
|
|
1,347
|
|
Share
premium account
|
|
|
3,436
|
|
3,301
|
|
Retained
earnings
|
|
|
9,637
|
|
7,944
|
|
Other
reserves
|
|
|
1,761
|
|
2,463
|
|
|
|
|
|
|
|
|
Shareholders’ equity
|
|
|
16,181
|
|
15,055
|
|
|
|
|
|
|
|
|
Non-controlling
interests
|
|
|
6,451
|
|
6,287
|
|
|
|
|
|
|
|
|
TOTAL EQUITY
|
|
|
22,632
|
|
21,342
|
|
|
|
|
|
|
|
|
Statement of changes in
equity
|
|
|
Share
capital
£m
|
|
Share
premium
£m
|
|
Retained
earnings
£m
|
|
Other
reserves
£m
|
|
Share-
holder’s
equity
£m
|
|
Non-
controlling
interests
£m
|
|
Total
equity
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2022
|
1,347
|
|
3,301
|
|
7,944
|
|
2,463
|
|
15,055
|
|
6,287
|
|
21,342
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
1,802
|
|
|
|
1,802
|
|
365
|
|
2,167
|
|
Other
comprehensive
income/(expense)
for the period
|
|
|
|
|
507
|
|
(347)
|
|
160
|
|
4
|
|
164
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income/(expense)
for
the period
|
|
|
|
|
2,309
|
|
(347)
|
|
1,962
|
|
369
|
|
2,331
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(213)
|
|
(213)
|
|
Contributions
from non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
8
|
|
8
|
|
Dividends
to shareholders
|
|
|
|
|
(952)
|
|
|
|
(952)
|
|
|
|
(952)
|
|
Shares
issued
|
|
|
17
|
|
|
|
|
|
17
|
|
|
|
17
|
|
Shares
acquired by ESOP Trusts
|
|
|
118
|
|
704
|
|
(822)
|
|
-
|
|
|
|
-
|
|
Realised
after tax losses on disposal
of
equity investments
|
|
|
|
|
(10)
|
|
10
|
|
-
|
|
|
|
-
|
|
Write-down
on shares held by ESOP
Trusts
|
|
|
|
|
(457)
|
|
457
|
|
-
|
|
|
|
-
|
|
Share-based
incentive plans
|
|
|
|
|
99
|
|
|
|
99
|
|
|
|
99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 31 March 2022
|
1,347
|
|
3,436
|
|
9,637
|
|
1,761
|
|
16,181
|
|
6,451
|
|
22,632
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 1
January 2021
|
1,346
|
|
3,281
|
|
6,755
|
|
3,205
|
|
14,587
|
|
6,221
|
|
20,808
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
for the period
|
|
|
|
|
1,073
|
|
|
|
1,073
|
|
187
|
|
1,260
|
|
Other
comprehensive (expense)/
income
for the period
|
|
|
|
|
(255)
|
|
292
|
|
37
|
|
(34)
|
|
3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
comprehensive income for the
period
|
|
|
|
|
818
|
|
292
|
|
1,110
|
|
153
|
|
1,263
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Distributions
to non-controlling interests
|
|
|
|
|
|
|
|
|
|
|
(236)
|
|
(236)
|
|
Contributions
from non-controlling
interests
|
|
|
|
|
|
|
|
|
|
|
7
|
|
7
|
|
Dividends
to shareholders
|
|
|
|
|
(946)
|
|
|
|
(946)
|
|
|
|
(946)
|
|
Shares
issued
|
|
|
15
|
|
|
|
|
|
15
|
|
|
|
15
|
|
Realised
after tax profits on disposal
of
equity investments
|
|
|
|
|
29
|
|
(29)
|
|
-
|
|
|
|
-
|
|
Write-down
on shares held by ESOP
Trusts
|
|
|
|
|
(55)
|
|
55
|
|
-
|
|
|
|
-
|
|
Share-based
incentive plans
|
|
|
|
|
99
|
|
|
|
99
|
|
|
|
99
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
At 31
March 2021
|
1,346
|
|
3,296
|
|
6,700
|
|
3,523
|
|
14,865
|
|
6,145
|
|
21,010
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash flow
statement
|
|
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
|
|
|
|
|
|
|
Profit after tax
|
2,167
|
|
1,260
|
|
|
Tax on
profits
|
431
|
|
258
|
|
|
Share
of after tax (losses)/profits of associates and joint
ventures
|
1
|
|
(16)
|
|
|
Net
finance expense
|
202
|
|
191
|
|
|
Depreciation,
amortisation and other adjusting items
|
704
|
|
361
|
|
|
Decrease
in working capital
|
(671)
|
|
(539)
|
|
|
Contingent
consideration paid
|
(185)
|
|
(192)
|
|
|
Increase/(decrease)
in other net liabilities (excluding contingent
consideration
paid)
|
106
|
|
(837)
|
|
|
|
|
|
|
|
|
Cash generated from operations
|
2,755
|
|
486
|
|
|
Taxation
paid
|
(213)
|
|
(155)
|
|
|
|
|
|
|
|
|
Net cash inflow from operating activities
|
2,542
|
|
331
|
|
|
|
|
|
|
|
|
Cash flow from investing activities
|
|
|
|
|
|
Purchase
of property, plant and equipment
|
(222)
|
|
(201)
|
|
|
Proceeds
from sale of property, plant and equipment
|
6
|
|
37
|
|
|
Purchase
of intangible assets
|
(379)
|
|
(153)
|
|
|
Proceeds
from sale of intangible assets
|
9
|
|
328
|
|
|
Purchase
of equity investments
|
(45)
|
|
(103)
|
|
|
Proceeds
from sale of equity investments
|
-
|
|
44
|
|
|
Contingent
consideration paid
|
(26)
|
|
(29)
|
|
|
Disposal
of businesses
|
1
|
|
3
|
|
|
Cash
advances and loans to third parties
|
(2,947)
|
|
-
|
|
|
Interest
received
|
10
|
|
8
|
|
|
Decrease
in liquid investments
|
-
|
|
18
|
|
|
|
|
|
|
|
|
Net cash outflow from investing activities
|
(3,593)
|
|
(48)
|
|
|
|
|
|
|
|
|
Cash flow from financing activities
|
|
|
|
|
|
Issue
of share capital
|
17
|
|
15
|
|
|
Shares
acquired by ESOP Trusts
|
(5)
|
|
-
|
|
|
Increase
in long-term loans
|
9,205
|
|
-
|
|
|
Repayment
of short-term loans
|
(249)
|
|
(5)
|
|
|
Repayment
of lease liabilities
|
(59)
|
|
(49)
|
|
|
Interest
paid
|
(85)
|
|
(95)
|
|
|
Dividends
paid to shareholders
|
(952)
|
|
(946)
|
|
|
Distributions
to non-controlling interests
|
(213)
|
|
(236)
|
|
|
Contributions
from non-controlling interests
|
8
|
|
7
|
|
|
Other
financing items
|
306
|
|
(67)
|
|
|
|
|
|
|
|
|
Net cash inflow/(outflow) from financing activities
|
7,973
|
|
(1,376)
|
|
|
|
|
|
|
|
|
Increase/(decrease) in cash and bank overdrafts in the
period
|
6,922
|
|
(1,093)
|
|
|
|
|
|
|
|
|
Cash
and bank overdrafts at beginning of the period
|
3,817
|
|
5,262
|
|
|
Exchange
adjustments
|
12
|
|
(35)
|
|
|
Increase/(decrease)
in cash and bank overdrafts
|
6,922
|
|
(1,093)
|
|
|
|
|
|
|
|
|
Cash and bank overdrafts at end of the period
|
10,751
|
|
4,134
|
|
|
|
|
|
|
|
|
Cash
and bank overdrafts at end of the period comprise:
|
|
|
|
|
|
|
Cash
and cash equivalents
|
10,967
|
|
4,757
|
|
|
Overdrafts
|
(216)
|
|
(623)
|
|
|
|
|
|
|
|
|
10,751
|
|
4,134
|
|
|
|
|
|
|
|
|
Segment
information
|
|
Operating
segments are reported based on the financial information provided
to the Chief Executive Officer and the responsibilities of the GSK
Leadership Team (GLT). GSK has revised its operating segments from
Q1 2022. Previously, GSK reported results under four segments:
Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer
Healthcare. From the first quarter 2022, GSK reports results under
three segments: Commercial Operations; Total R&D and Consumer
Healthcare, and members of the GLT are responsible for each
segment. Comparative information in this announcement has been
retrospectively restated on a consistent basis.
R&D
investment is essential for the sustainability of the business.
However for segment reporting the Commercial operating profits
exclude allocations of globally funded R&D.
The
Total R&D segment is the responsibility of the Chief Scientific
Officer and President, R&D and is reported as a separate
segment. The operating profit of this segment includes R&D
activities across Specialty Medicines, including HIV and Vaccines.
It includes R&D and some SG&A costs relating to regulatory
and other functions.
The
Group’s management reporting process allocates intra-Group
profit on a product sale to the market in which that sale is
recorded, and the profit analyses below have been presented on that
basis.
|
|
Turnover by segment
|
|||||||
|
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
7,147
|
|
5,106
|
|
40
|
|
40
|
|
Consumer
Healthcare
|
2,633
|
|
2,312
|
|
14
|
|
14
|
|
|
|
|
|
|
|
|
|
|
Total
turnover
|
9,780
|
|
7,418
|
|
32
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment
|
|||||||
|
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
Growth
£%
|
|
Growth
CER%
|
|
|
|
|
|
|
|
|
|
|
Commercial
Operations
|
3,121
|
|
2,451
|
|
27
|
|
27
|
|
Research
and Development
|
(1,095)
|
|
(1,030)
|
|
6
|
|
6
|
|
Consumer
Healthcare
|
650
|
|
535
|
|
21
|
|
26
|
|
|
|
|
|
|
|
|
|
|
Segment
profit
|
2,676
|
|
1,956
|
|
37
|
|
38
|
|
Corporate
and other unallocated costs
|
(63)
|
|
(75)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted
operating profit
|
2,613
|
|
1,881
|
|
39
|
|
39
|
|
Adjusting
items
|
188
|
|
(188)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
operating profit
|
2,801
|
|
1,693
|
|
65
|
|
65
|
|
|
|
|
|
|
|
|
|
|
Finance
income
|
10
|
|
10
|
|
|
|
|
|
Finance
costs
|
(212)
|
|
(201)
|
|
|
|
|
|
Share
of after tax (losses)/profits of
associates
and joint ventures
|
(1)
|
|
16
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit
before taxation
|
2,598
|
|
1,518
|
|
71
|
|
71
|
|
|
|
|
|
|
|
|
|
|
Adjusting items reconciling segment profit and operating profit
comprise items not specifically allocated to segment profit. These
include impairment and amortisation of intangible assets; major
restructuring costs, which include impairments of tangible assets
and computer software; transaction-related adjustments related to
significant acquisitions; proceeds and costs of disposals of
associates, products and businesses, significant legal charges and
expenses on the settlement of litigation and government
investigations, other operating income other than royalty income
and other items, and separation costs.
|
|
Legal matters
The
Group is involved in significant legal and administrative
proceedings, principally product liability, intellectual property,
tax, anti-trust, consumer fraud and governmental investigations,
which are more fully described in the ‘Legal
Proceedings’ note in the Annual Report 2021. At 31 March
2022, the Group’s aggregate provision for legal and other
disputes (not including tax matters described on page 14) was
£0.2 billion (31 December 2021: £0.2
billion).
The
Group may become involved in significant legal proceedings in
respect of which it is not possible to meaningfully assess whether
the outcome will result in a probable outflow, or to quantify or
reliably estimate the liability, if any, that could result from
ultimate resolution of the proceedings. In these cases, the Group
would provide appropriate disclosures about such cases, but no
provision would be made.
The
ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation
proceedings, investigations and possible settlement negotiations.
The Group’s position could change over time, and, therefore,
there can be no assurance that any losses that result from the
outcome of any legal proceedings will not exceed by a material
amount the amount of the provisions reported in the Group’s
financial accounts.
Significant
developments since the date of the Annual Report 2021 are as
follows:
Dovato
In
September 2019, ViiV Healthcare received a paragraph IV letter from
Cipla Ltd. (Cipla) relating to Dovato and challenging only the crystal
form patent. On 4 November 2019, ViiV Healthcare filed suit against
Cipla in the US District Court for the District of Delaware. In
March 2022, the parties reached a settlement, thereby concluding
the matter.
Juluca
In
January 2020, ViiV Healthcare received a paragraph IV letter from
Lupin Ltd. (Lupin) relating to Juluca and challenging the crystal form
patent as well as a patent relating to the combination of
dolutegravir and rilpivirine that expires on 24 January 2031. On 28
February 2020, ViiV Healthcare filed suit against Lupin on both
patents. In March 2022, the parties reached a settlement, thereby
concluding the matter.
|
|
Additional
information
|
|
Accounting policies and basis of preparation
|
|
This
unaudited Results Announcement contains condensed financial
information for the three months ended
31 March 2022, and should be read in conjunction with the Annual
Report 2021, which was prepared in accordance with
United
Kingdom adopted International Financial Reporting Standards.
This Results Announcement has been prepared applying consistent
accounting policies to those applied by the Group in the Annual
Report 2021.
The
Group has not identified any changes to its key sources of
accounting judgements or estimations of uncertainty compared with
those disclosed in the Annual Report 2021.
|
|
This
Results Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The full Group accounts for 2021 were published
in the Annual Report 2021, which has been delivered to the
Registrar of Companies and on which the report of the independent
auditor was unqualified and did not contain a statement under
section 498 of the Companies Act 2006.
COVID-19 pandemic
The potential impact of the COVID-19 pandemic on GSK’s
trading performance and all its principal risks have been assessed,
with appropriate mitigation plans put in place. GSK is encouraged
by the uptake in demand in the first quarter for its medicines and
vaccines, particularly Shingrix. Overall, the Company remains confident in the
underlying demand for its medicines and vaccines. GSK is encouraged
by the rate at which COVID-19 vaccinations and boosters have been
administered worldwide, providing support for healthcare systems
ahead of the anticipated return to normal. This continues, however,
to be a dynamic situation with the risk of future variants of
concern unknown; these variants of concern could potentially impact
GSK’s trading results, clinical trials, supply continuity,
and its employees materially.
|
|
Exchange rates
|
|
GSK
operates in many countries, and earns revenues and incurs costs in
many currencies. The results of the Group, as reported in Sterling,
are affected by movements in exchange rates between Sterling and
other currencies. Average exchange rates, as modified by specific
transaction rates for large transactions, prevailing during the
period, are used to translate the results and cash flows of
overseas subsidiaries, associates and joint ventures into Sterling.
Period-end rates are used to translate the net assets of those
entities. The currencies which most influenced these translations
and the relevant exchange rates were:
|
|
|
Q1 2022
|
|
Q1
2021
|
|
2021
|
||
|
|
|
|
|
|
|
||
|
Average
rates:
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.34
|
|
1.38
|
|
1.38
|
|
|
|
Euro/£
|
1.19
|
|
1.14
|
|
1.16
|
|
|
|
Yen/£
|
156
|
|
146
|
|
151
|
|
|
|
|
|
|
|
||
|
Period-end
rates:
|
|
|
|
|
|
||
|
|
|
US$/£
|
1.31
|
|
1.38
|
|
1.35
|
|
|
|
Euro/£
|
1.18
|
|
1.17
|
|
1.19
|
|
|
|
Yen/£
|
160
|
|
152
|
|
155
|
|
During Q1 2022 average Sterling exchange rates were stronger
against the Yen and the Euro but weaker against the US Dollar
compared with the same period in 2021. Period-end Sterling exchange
rates were stronger against the Euro and the Yen and weaker against
the US Dollar compared with the 2021 period-end rates.
|
|
Name change
|
|
GSK
announces that it will change its company name to GSK plc from
GlaxoSmithKline plc from a date in mid-May. A subsequent
announcement will be made when the name change becomes effective.
The company’s stock ticker on the LSE and NYSE
(“GSK”) will not change. No action is required on the
part of any equity holders with respect to their rights as an
equity holder.
|
|
Net assets
|
|
The
book value of net assets increased by £1,290 million from
£21,342 million at 31 December 2021 to £22,632 million at
31 March 2022. This primarily reflected the Total profit for the
period, the re-measurement gains on the defined benefit plans plus
an increase in intangible assets, other non-current assets and
trade receivables. These increases were partially offset by the
decrease in fair value of equity investments and the dividends paid
during the period. Cash and cash equivalents and long term
borrowings increased due to the Consumer Healthcare bond debt
issuance.
The
carrying value of investments in associates and joint ventures at
31 March 2022 was £83 million (31 December 2021: £88
million), with a market value of £83 million (31 December
2021: £88 million).
At 31
March 2022, the net deficit on the Group’s pension plans was
£914 million compared with £1,129 million at 31 December
2021. The decrease in the net deficit primarily relate to increase
in the rates used to discount UK pension liabilities from 2.0% to
2.8%, and US pension liabilities from 2.7% to 3.7%, partly offset
by an increase in the UK inflation rate from 3.2% to 3.5%, increase
in the US cash balance credit rate from 2.0% to 2.4% and lower UK
asset values.
The
estimated present value of the potential redemption amount of the
Pfizer put option related to ViiV Healthcare, recorded in Other
payables in Current liabilities, was £1,040 million (31
December 2021: £1,008 million).
Contingent
consideration amounted to £6,169 million at 31 March 2022 (31
December 2021: £6,076 million), of which £5,607 million
(31 December 2021: £5,559 million) represented the estimated
present value of amounts payable to Shionogi relating to ViiV
Healthcare and £529 million (31 December 2021: £479
million) represented the estimated present value of contingent
consideration payable to Novartis related to the Vaccines
acquisition.
Of the
contingent consideration payable (on a post-tax basis) to Shionogi
at 31 March 2022, £947 million (31 December 2021: £937
million) is expected to be paid within one year.
|
|
Movements in contingent consideration are as follows:
|
|
Q1
2022
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,559
|
|
6,076
|
|
Re-measurement
through income statement
|
256
|
|
304
|
|
Cash
payments: operating cash flows
|
(183)
|
|
(185)
|
|
Cash
payments: investing activities
|
(25)
|
|
(26)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,607
|
|
6,169
|
|
|
|
|
|
|
Q1 2021
|
ViiV
Healthcare
£m
|
|
Group
£m
|
|
|
|
|
|
|
Contingent
consideration at beginning of the period
|
5,359
|
|
5,869
|
|
Re-measurement
through income statement
|
134
|
|
160
|
|
Cash
payments: operating cash flows
|
(189)
|
|
(192)
|
|
Cash
payments: investing activities
|
(27)
|
|
(29)
|
|
|
|
|
|
|
Contingent
consideration at end of the period
|
5,277
|
|
5,808
|
|
|
|
|
|
|
Contingent liabilities
|
|
There
were contingent liabilities at 31 March 2022 in respect of
guarantees and indemnities entered into as part of the ordinary
course of the Group’s business. No material losses are
expected to arise from such contingent liabilities. Provision is
made for the outcome of legal and tax disputes where it is both
probable that the Group will suffer an outflow of funds and it is
possible to make a reliable estimate of that outflow. Descriptions
of the significant legal disputes to which the Group is a party are
set out on page 30.
|
|
Business acquisitions
|
|
On 13 April 2022, GSK announced it had reached agreement to acquire
Sierra Oncology, Inc. a California-based, late-stage
biopharmaceutical company focused on targeted therapies for the
treatment of rare forms of cancer, for $55 per share of common
stock in cash representing an approximate total equity value of
$1.9 billion (£1.5 billion). Under the terms of the agreement,
the acquisition will be effected through a one-step merger in which
the shares of Sierra Oncology outstanding will be cancelled and
converted into the right to receive $55 per share in cash. Subject
to customary conditions, including the approval of the merger by at
least a majority of the issued and outstanding shares of Sierra
Oncology, and the expiration or earlier termination of the waiting
period under the Hart-Scott-Rodino Antitrust Improvements Act of
1976, the transaction is expected to close in the third quarter of
2022 or before.
|
|
Reconciliation of cash flow to
movements in net debt
|
|
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
|
|
|
|
|
Net
debt at beginning of the period
|
(19,838)
|
|
(20,780)
|
|
|
|
|
|
|
Increase/(decrease)
in cash and bank overdrafts
|
6,922
|
|
(1,093)
|
|
Decrease
in liquid investments
|
-
|
|
(18)
|
|
Net
decrease in short-term loans
|
249
|
|
5
|
|
Increase
in long-term loans
|
(9,205)
|
|
-
|
|
Repayment
of lease liabilities
|
59
|
|
49
|
|
Cash
advances and loans to third parties
|
2,947
|
|
-
|
|
Exchange
adjustments
|
(427)
|
|
466
|
|
Other
non-cash movements
|
(58)
|
|
(31)
|
|
|
|
|
|
|
Decrease
in net debt
|
487
|
|
(622)
|
|
|
|
|
|
|
Net
debt at end of the period
|
(19,351)
|
|
(21,402)
|
|
|
|
|
|
|
Net debt analysis
|
|
|
31 March 2022
£m
|
|
31
December 2021
£m
|
|
|
|
|
|
|
Liquid
investments
|
63
|
|
61
|
|
Cash
and cash equivalents
|
10,967
|
|
4,274
|
|
Cash
advances and loans to third parties
|
2,947
|
|
-
|
|
Short-term
borrowings
|
(4,102)
|
|
(3,601)
|
|
Long-term
borrowings
|
(29,226)
|
|
(20,572)
|
|
|
|
|
|
|
Net
debt at end of the period
|
(19,351)
|
|
(19,838)
|
|
|
|
|
|
|
Free cash flow
reconciliation
|
|
|
Q1 2022
£m
|
|
Q1
2021
£m
|
|
|
|
|
|
|
Net
cash inflow from operating activities
|
2,542
|
|
331
|
|
Purchase
of property, plant and equipment
|
(222)
|
|
(201)
|
|
Proceeds
from sale of property, plant and equipment
|
6
|
|
37
|
|
Purchase
of intangible assets
|
(379)
|
|
(153)
|
|
Proceeds
from disposals of intangible assets
|
9
|
|
328
|
|
Net
finance costs
|
(75)
|
|
(87)
|
|
Dividends
from joint ventures and associates
|
-
|
|
-
|
|
Contingent
consideration paid (reported in investing activities)
|
(26)
|
|
(29)
|
|
Distributions
to non-controlling interests
|
(213)
|
|
(236)
|
|
Contributions
from non-controlling interests
|
8
|
|
7
|
|
|
|
|
|
|
Free
cash flow
|
1,650
|
|
(3)
|
|
|
|
|
|
|
R&D commentary
|
|
GSK focuses on the science of the immune system, human genetics,
and advanced technologies to develop Specialty Medicines and
Vaccines in four core therapeutic areas – Infectious
Diseases, HIV, Oncology and Immunology. GSK remains open to
opportunities outside of these core therapy areas, specifically
those opportunities that are aligned to the Company’s focus
on the science of the immune system and human genetic validation.
The table below highlights medicines and vaccines in late-stage
(phase III) development by therapy area:
|
|
Pipeline overview
|
|
Medicines
and vaccines in phase III development (including major lifecycle
innovation or under regulatory review)
|
21
|
Infectious Diseases (11)
|
|
|
●
|
Bexsero infants (US) vaccine
|
||
|
●
|
COVID-19
(Medicago) vaccine candidate
|
||
|
●
|
COVID-19
(Sanofi) vaccine candidate
|
||
|
●
|
COVID-19
(SK Bioscience) vaccine candidate
|
||
|
●
|
MenABCWY
(1st gen) vaccine candidate
|
||
|
●
|
Menveo liquid vaccine
|
||
|
●
|
MMR
(US) vaccine
|
||
|
●
|
Rotarix liquid (US) vaccine
|
||
|
●
|
RSV
older adults vaccine candidate
|
||
|
●
|
gepotidacin
(bacterial topoisomerase inhibitor) uUTIand GC
|
||
|
●
|
Xevudy (sotrovimab/VIR-7831) COVID-19
|
||
|
|
|
||
|
Oncology (4)
|
|||
|
●
|
Blenrep (anti-BCMA ADC) multiple myeloma
|
||
|
●
|
Jemperli (PD-1 antagonist) 1L endometrial
cancer
|
||
|
●
|
Zejula (PARP inhibitor) 1L ovarian, lung and breast
cancer
|
||
|
●
|
letetresgene-autoleucel
(NY-ESO-1 TCR) synovial sarcoma/myxoid/round cell
liposarcoma
|
||
|
|
|
||
|
Immunology (4)
|
|||
|
●
|
latozinemab
(AL001, anti-sortilin) frontotemporal dementia
|
||
|
●
|
depemokimab
(LA anti-IL5 antagonist) asthma, eosinophilic granulomatosis with
polyangiitis, chronic rhinosinusitis with nasal polyps
|
||
|
●
|
Nucala chronic obstructive pulmonary disease
|
||
|
●
|
otilimab
(aGM-CSF inhibitor) rheumatoid arthritis
|
||
|
|
|
||
|
Opportunity driven (2)
|
|||
|
●
|
daprodustat
(HIF-PHI) anaemia of chronic kidney disease
|
||
|
●
|
linerixibat
(IBATi) cholestatic pruritus in primary biliary
cholangitis
|
||
|
Total
vaccines and medicines in all phases of clinical
development
|
64
|
|
|
|
Total
projects in clinical development (inclusive of all phases and
indications)
|
79
|
|
|
|
Our key growth assets by
therapy area
|
|
The following outlines several key medicines and vaccines by
therapy area that will help drive growth for GSK to meet its
outlooks and ambition for 2021-2026 and beyond.
|
|
Infectious Diseases
|
|
bepirovirsen (HBV
ASO)
|
|
GSK is investigating bepirovirsen for the treatment of chronic
hepatitis B both as a monotherapy (B-Clear) and in combination with
existing treatments (B-Together) with the aim to explore additional
combinations in the future. In April 2022, the Company began the
first phase II combination trial of bepirovirsen and a hepatitis B
virus targeted immunotherapy.
|
|
Key
trials for bepirovirsen:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
B-Clear bepirovirsen monotherapy (chronic hepatitis B)
NCT04449029
|
IIb
|
A multi-centre, randomised, partial-blind parallel cohort study to
assess the efficacy and safety of treatment with bepirovirsen in
participants with chronic hepatitis B virus
|
Trial start:
Q3 2020
|
Active, not recruiting
|
|
B-Together bepirovirsen sequential combination therapy with
Peg-interferon phase II (chronic hepatitis B)
NCT04676724
|
II
|
A multi-centre, randomised, open label study to assess the efficacy
and safety of sequential treatment with bepirovirsen followed by
Pegylated Interferon Alpha 2a in participants with chronic
hepatitis B virus
|
Trial start:
Q1 2021
|
Active, not recruiting
|
|
Bepirovirsen sequential combination therapy with targeted
immunotherapy
(chronic hepatitis B)
NCT05276297
|
II
|
A study on the safety, efficacy and immune response following
sequential treatment with an anti-sense oligonucleotide against
chronic hepatitis B (CHB) and chronic hepatitis B targeted
immunotherapy (CHB-TI) in CHB patients receiving nucleos(t)ide
analogue (NA) therapy
|
Trial start:
Q2 2022
|
Active,
recruiting
|
|
gepotidacin (bacterial topoisomerase inhibitor)
|
|
First in class novel antibiotic for the treatment of uncomplicated
urinary tract infections (uUTI) and gonorrhea. Interim analysis for
EAGLE is scheduled in the second half of 2022.
|
|
Key
phase III trials for gepotidacin:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
EAGLE-1 (uncomplicated urogenital gonorrhea)
NCT04010539
|
III
|
A randomised, multi-centre, open-label study in adolescent and
adult participants comparing the efficacy and safety of gepotidacin
to ceftriaxone plus azithromycin in the treatment of uncomplicated
urogenital gonorrhea caused by neisseria gonorrhoeae
|
Trial start:
Q4 2019
|
Recruiting
|
|
EAGLE-2 (females with uUTI / acute cystitis)
NCT04020341
|
III
|
A randomised, multi-centre, parallel-group, double-blind,
double-dummy study in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial start:
Q4 2019
|
Recruiting
|
|
EAGLE-3 (females with uUTI / acute cystitis)
NCT04187144
|
III
|
A randomised, multi-centre, parallel-group, double-blind,
double-dummy study in adolescent and adult female participants
comparing the efficacy and safety of gepotidacin to nitrofurantoin
in the treatment of uncomplicated urinary tract infection (acute
cystitis)
|
Trial start:
Q4 2019
|
Recruiting
|
|
MenABCWY vaccine candidate:
|
|
GSK is
developing two MenABCWY pentavalent (5-in-1) vaccines, the first
generation is in late-stage development, the second generation in
an earlier stage. The goal is to help protect against all five
major disease-causing serogroups. Phase III pivotal results from
the first generation MenABCWY vaccine are expected in the second
half of this year.
|
|
Key
phase III trials for MenABCWY vaccine candidate:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
MenABCWY – 019
NCT04707391
|
IIIb
|
A randomised, controlled, observer-blind study to evaluate safety
and immunogenicity of GSK’s meningococcal ABCWY vaccine when
administered in healthy adolescents and adults, previously primed
with meningococcal ACWY vaccine
|
Trial start:
Q1 2021
|
Recruiting
|
|
MenABCWY – V72 72
NCT04502693
|
III
|
A randomised, controlled, observer-blind study to demonstrate
effectiveness, immunogenicity and safety of GSK's meningococcal
Group B and combined ABCWY vaccines when administered to healthy
adolescents and young adults
|
Trial
start:
Q3
2020
|
Active, not recruiting
|
|
RSV vaccine candidates
|
|
In
February 2022, GSK stopped enrolment and vaccination in trials
evaluating its potential respiratory syncytial virus (RSV) maternal
vaccine candidate in pregnant women. This decision does not impact
the ongoing phase III trial for RSV older adults (60 years and
above). This trial remains on track with an anticipated data
readout in the first half of 2022.
|
|
Key
phase III trials for RSV older adult and maternal vaccine
candidates:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RSV OA-004
(Adults ≥60
yo)
NCT04732871
|
III
|
A randomised, open-label, multi-country study to evaluate the
immunogenicity, safety, reactogenicity and persistence of a single
dose of the RSVPreF3 OA investigational vaccine and different
revaccination schedules in adults aged 60 years and
above
|
Trial start:
Q1 2021
|
Active, not recruiting
|
|
RSV OA-006
(Adults ≥60
yo)
NCT04886596
|
III
|
A randomised, placebo-controlled, observer-blind, multi-country
study to demonstrate the efficacy of a single dose of GSK’s
RSVPreF3 OA investigational vaccine in adults aged 60 years and
above
|
Trial start:
Q2 2021
|
Active, not recruiting
|
|
RSV OA-007
(Adults ≥60
yo)
NCT04841577
|
III
|
An open-label, randomised, controlled, multi-country study to
evaluate the immune response, safety and reactogenicity of RSVPreF3
OA investigational vaccine when co-administered with FLU-QIV
vaccine in adults aged 60 years and above
|
Trial start:
Q2 2021
|
Complete; results anticipated to be shared 2022+
|
|
RSV OA-009
(Adults ≥60
yo)
NCT05059301
|
III
|
A randomised, double-blind, multi-country study to evaluate
consistency, safety, and reactogenicity of 3 lots of RSVPreF3 OA
investigational vaccine administrated as a single dose in adults
aged 60 years and above
|
Trial start:
Q4 2021
|
Active, not recruiting
|
|
GRACE (pregnant women aged 14-49 yo)
NCT04605159
|
III
|
A randomised, double-blind, placebo-controlled multi-country study
to demonstrate efficacy of a single dose of unadjuvanted RSV
maternal vaccine, administered IM to pregnant women 18 to 49 years
of age, for prevention of RSV associated LRTIs in their infants up
to 6 months of age
|
Trial start:
Q4 2020
Trial stopped enrolment and vaccination:
Q1 2022
|
Stopped enrolment and vaccination
|
|
HIV
|
|
cabotegravir
|
|
In March 2022, the US Food and Drug Administration (FDA) approved
an updated label for Cabenuva (cabotegravir, rilpivirine) that streamlines the
initiation process for the first and only complete long-acting HIV
treatment by allowing people to start directly with injections
without an optional oral lead-in period. Additionally, the US FDA also approved
Cabenuva
for the treatment of HIV-1 in
virologically suppressed adolescents (HIV-1 RNA less than 50 copies
per millilitre [c/mL]) who are 12 years of age or older and weigh
at least 35kg on a stable antiretroviral regimen, with no history
of treatment failure, and with no known or suspected resistance to
either cabotegravir or rilpivirine.
At the Conference on Retroviruses and Opportunistic
Infections 2022, held virtually on 12-16 February, GSK
presented data demonstrating further evidence for the long-acting
regimen of Cabenuva administered every two months. This included the
ATLAS-2M 152-week efficacy and safety findings for the treatment of
HIV-1 in virologically suppressed adults, which builds upon
previous 96-week efficacy and safety data. An
investigator-sponsored analysis of adolescent perspectives toward
the long-acting regimen was also presented.
|
|
Key
phase III trials for cabotegravir:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
HPTN 083
(HIV uninfected cisgender men and transgender women who have sex
with men)
NCT02720094
|
III
|
A double-blind safety and efficacy study of injectable cabotegravir
compared to daily oral tenofovir disoproxil fumarate/emtricitabine
(TDF/FTC), for Pre-Exposure Prophylaxis in HIV-uninfected cisgender
men and transgender women who have sex with men
|
Trial start:
Q4 2016
|
Active; not recruiting; primary endpoint met
(superiority)
|
|
HPTN 084
(HIV uninfected women who are at high risk of acquiring
HIV)
NCT03164564
|
III
|
A double-blind safety and efficacy study of long-acting injectable
cabotegravir compared to daily oral TDF/FTC for Pre-Exposure
Prophylaxis in HIV-Uninfected women
|
Trial start:
Q4 2017
|
Active; not recruiting; primary endpoint met
(superiority)
|
|
ATLAS
NCT02951052
|
III
|
A randomised, multi-centre, parallel-group, non-inferiority,
open-label study evaluating the efficacy, safety, and tolerability
of switching to long-acting cabotegravir plus long-acting
rilpivirine from current INI- NNRTI-, or PI-based antiretroviral
regimen in HIV-1-infected adults who are virologically
suppressed
|
Trial start:
Q4 2016
|
Active; not recruiting; primary endpoint met
(non-inferiority)
|
|
ATLAS-2M
NCT03299049
|
IIIb
|
A randomised, multi-centre, parallel-group, non-inferiority,
open-label study evaluating the efficacy, safety, and tolerability
of long-acting cabotegravir plus long-acting rilpivirine
administered every 8 weeks or every 4 weeks in HIV-1-infected
adults who are virologically suppressed
|
Trial start:
Q4 2017
|
Active; not recruiting; primary endpoint met
(non-inferiority)
|
|
FLAIR
NCT02938520
|
III
|
A randomised, multi-centre, parallel-group, open-label study
evaluating the efficacy, safety, and tolerability of long-acting
intramuscular cabotegravir and rilpivirine for maintenance of
virologic suppression following switch from an integrase inhibitor
single tablet regimen in HIV-1 infected antiretroviral therapy
naive adult participants
|
Trial
start:
Q4
2016
|
Active; not recruiting; primary endpoint met
(non-inferiority)
|
|
Oncology
|
|
Blenrep
(belantamab mafodotin)
|
|
GSK is
continuing the DREAMM clinical development programme evaluating the
potential of Blenrep in a broader
multiple myeloma (MM) patient population, including as a
monotherapy and in combination with standard and novel therapies in
earlier lines of treatment.
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
DREAMM-3 (3L/4L+ MM pts who have failed Len + PI)
NCT04162210
|
III
|
An open-label, randomised study to evaluate the efficacy and safety
of single agent belantamab mafodotin compared to pomalidomide plus
low dose dexamethasone (pom/dex) in participants with
relapsed/refractory multiple myeloma
|
Trial start:
Q2 2020
|
Recruiting
|
|
DREAMM-7 (2L+ MM pts)
NCT04246047
|
III
|
A multi-centre, open-label, randomised study to evaluate the
efficacy and safety of the combination of belantamab mafodotin,
bortezomib, and dexamethasone (B-Vd) compared with the combination
of daratumumab, bortezomib and dexamethasone (D-Vd) in participants
with relapsed/refractory multiple myeloma
|
Trial start:
Q2 2020
|
Active, not recruiting
|
|
DREAMM-8 (2L+ MM pts)
NCT04484623
|
III
|
A multi-centre, open-label, randomised study to evaluate the
efficacy and safety of belantamab mafodotin in combination with
pomalidomide and dexamethasone (B-Pd) versus pomalidomide plus
bortezomib and dexamethasone (P-Vd) in participants with
relapsed/refractory multiple myeloma
|
Trial start:
Q4 2020
|
Recruiting
|
|
Jemperli
(dostarlimab)
|
|
New data for Jemperli was presented at the Society of Gynaecologic
Oncology (SGO) 2022 Annual Meeting on Women’s Cancer, held on
18-21 March, in Phoenix, Arizona. A GARNET trial subgroup
presentation included a post-hoc analysis evaluating the antitumour activity and
safety of Jemperli in patients with endometrial cancer by age
subgroups. Additionally, a Jemperli indirect treatment comparison compared the
clinical effectiveness of Jemperli in combination with doxorubicin, a chemotherapy
medicine, in the treatment of advanced or recurrent endometrial
cancer, which may help further contextualize how
Jemperli
fits in the recurrent or advanced
mismatch repair-deficient (dMMR) endometrial cancer treatment
landscape.
|
|
Key
phase III trials for Jemperli:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
RUBY
ENGOT-EN6
GOG-3031 (1L Stage III or IV endometrial cancer)
NCT03981796
|
III
|
A randomised, double-blind, multi-centre study of dostarlimab
(TSR-042) plus carboplatin-paclitaxel with and without niraparib
maintenance versus placebo plus carboplatin-paclitaxel in patients
with recurrent or primary advanced endometrial cancer
|
Trial start:
Q3 2019
|
Recruiting
|
|
Zejula
(niraparib)
|
|
New data presented at the SGO 2022 Annual Meeting on Women’s
Cancer included both the OVARIO and ROYAL trials. OVARIO featured
an updated analysis from this phase II study evaluating
Zejula
in combination with bevacizumab, an
anti-vascular endothelial growth factor antibody (VEGFA) targeted
cancer medicine, as first-line maintenance therapy in patients with
ovarian cancer following platinum-based chemotherapy and
bevacizumab. ROYAL was a real-world evidence study examining the
evolution of the ovarian cancer treatment paradigm in the US and
Europe from 2017 to 2020. The findings from this study showed that
the use of 1L maintenance PARP inhibitor monotherapy increased over
time and the use of VEGF inhibitor monotherapy decreased over time.
These findings also showed that many patients with advanced ovarian
cancer did not receive 1L maintenance therapy and treatment
patterns vary by country. In addition, GSK’s alliance partner
Zai Lab Limited presented a late-breaking oral presentation of the
PRIME phase III trial, which evaluated Zejula (independently manufactured by Zai Lab) in Chinese
patients with newly diagnosed advanced ovarian cancer using an
individualised starting dose. Zejula demonstrated a statistically significant and
clinically meaningful improvement in progression-free survival
(PFS) with a tolerable safety profile in the overall study
population, regardless of biomarker status, when compared to
placebo.
|
|
Key
phase III trials for Zejula:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ZEAL-1L (maintenance for 1L advanced NSCLC)
NCT04475939
|
III
|
A randomised, double-blind, placebo-controlled, multi-centre study
comparing niraparib plus pembrolizumab versus placebo plus
pembrolizumab as maintenance therapy in participants whose disease
has remained stable or responded to first-line platinum-based
chemotherapy with pembrolizumab for Stage IIIB/IIIC or IV non-small
cell lung cancer
|
Trial start:
Q4 2020
|
Recruiting
|
|
ZEST (Her2- with BRCA-mutation, or TNBC)
NCT04915755
|
III
|
A randomised double-blinded study comparing the efficacy and safety
of niraparib to placebo in participants with either HER2-negative
BRCA-mutated or triple-negative breast cancer with molecular
disease based on presence of circulating tumour DNA after
definitive therapy
|
Trial start:
Q2 2021
|
Recruiting
|
|
FIRST (1L ovarian cancer maintenance)
NCT03602859
|
III
|
A randomised, double-blind, comparison of platinum-based therapy
with dostarlimab (TSR-042) and niraparib versus standard of care
platinum-based therapy as first-line treatment of stage III or IV
nonmucinous epithelial ovarian cancer
|
Trial start:
Q4 2018
|
Active, not recruiting
|
|
Immunology
|
|
depemokimab (LA anti-IL5 antagonist)
|
|
In Q1 2022, GSK began initiating three additional phase III trials
for depemokimab in eosinophil diseases, one in eosinophilic
granulomatosis with polyangiitis (EGPA) and two in chronic
rhinosinusitis with nasal polyps (CRSwNP). A fourth study in
hypereosinophilic syndrome (HES) will be initiating in Q2
2022.
|
|
Key
phase III trials for depemokimab:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
SWIFT-1 (severe eosinophilic asthma)
NCT04719832
|
III
|
A 52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre study of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial start:
Q1 2021
|
Recruiting
|
|
SWIFT-2 (SEA)
NCT04718103
|
III
|
A 52-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre study of the efficacy and safety of
depemokimab adjunctive therapy in adult and adolescent participants
with severe uncontrolled asthma with an eosinophilic
phenotype
|
Trial start:
Q1 2021
|
Recruiting
|
|
NIMBLE (SEA)
NCT04718389
|
III
|
A 52-week, randomised, double-blind, double-dummy, parallel group,
multi-centre, non-inferiority study assessing exacerbation rate,
additional measures of asthma control and safety in adult and
adolescent severe asthmatic participants with an eosinophilic
phenotype treated with depemokimab compared with mepolizumab or
benralizumab
|
Trial start:
Q1 2021
|
Recruiting
|
|
ANCHOR-1 (CRSwNP)
NCT05274750
|
III
|
Efficacy and safety of depemokimab in participants with
CRSwNP
|
Initiating
|
Initiating
|
|
ANCHOR-2 (CRSwNP)
NCT05281523
|
III
|
Efficacy and safety of depemokimab in participants with
CRSwNP
|
Initiating
|
Initiating
|
|
OCEAN (EGPA)
NCT05263934
|
III
|
Efficacy and safety of depemokimab compared with mepolizumab in
adults with relapsing or refractory EGPA
|
Initiating
|
Initiating
|
|
otilimab (aGM-CSF inhibitor)
|
|
GSK is
investigating otilimab, an anti-GM-CSF monoclonal antibody, as a
potential new treatment for rheumatoid arthritis (RA). We expect to
report results from three phase III studies by the end of
2022.
|
|
Key
phase III trials for otilimab:
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
contRAst-1
(Moderate to severe RA MTX-IR patients)
NCT03980483
|
III
|
A 52-week, multi-centre, randomised, double blind, efficacy and
safety study comparing otilimab with placebo and with tofacitinib,
in combination with methotrexate in participants with moderately to
severely active rheumatoid arthritis who have an inadequate
response to methotrexate
|
Trial start:
Q2 2019
|
Active, not recruiting
|
|
contRAst-2 (Moderate to severe RA DMARD-IR patients)
NCT03970837
|
III
|
A 52-week, multi-centre, randomised, double blind, efficacy and
safety study, comparing otilimab with placebo and with tofacitinib
in combination with conventional synthetic DMARDs, in participants
with moderately to severely active rheumatoid arthritis who have an
inadequate response to conventional synthetic DMARDs or
biologic
|
Trial start:
Q2 2019
|
Active, not recruiting
|
|
contRAst-3 (Moderate to severe RA patients IR to biologic DMARD
and/or JAKs)
NCT04134728
|
III
|
A 24-week, multi-centre, randomised, double-blind, efficacy and
safety study, comparing otilimab with placebo and with sarilumab,
in combination with conventional synthetic DMARDs, in participants
with moderately to severely active rheumatoid arthritis who have an
inadequate response to biological DMARDs and/or Janus Kinase
inhibitors
|
Trial start:
Q4 2019
|
Complete; results anticipated to be shared H2 2022
|
|
Opportunity driven
|
|
daprodustat (oral hypoxia-inducible factor prolyl hydroxylase
inhibitor)
|
|
The
European Medicines Agency (EMA) validated the marketing
authorisation application (MAA) and the US FDA accepted the New
Drug Application (NDA) for daprodustat based on the positive data
from the ASCEND phase III clinical trial programme. The programme
included five pivotal trials assessing the efficacy and safety of
daprodustat for the treatment of anaemia of chronic kidney disease
(CKD). The data confirmed the potential of daprodustat as a new
oral medicine for patients with anaemia of CKD in both non-dialysis
and dialysis settings. The data were previously presented in
November 2021 at the American Society of Nephrology’s Kidney
Week 2021 and simultaneously published in the New England Journal
of Medicine.
|
|
Trial name (population)
|
Phase
|
Design
|
Timeline
|
Status
|
|
ASCEND-D (Dialysis subjects with anaemia of CKD)
NCT02879305
|
III
|
A randomised, open-label (sponsor-blind), active-controlled,
parallel-group, multi-centre, event driven study in dialysis
subjects with anemia associated with chronic kidney disease to
evaluate the safety and efficacy of daprodustat compared to
recombinant human erythropoietin, following a switch from
erythropoietin-stimulating agents
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-ID (Incident Dialysis subjects with anaemia of
CKD)
NCT03029208
|
III
|
A 52-week open-label (sponsor-blind), randomised,
active-controlled, parallel-group, multi-centre study to evaluate
the efficacy and safety of daprodustat compared to recombinant
human erythropoietin in subjects with anaemia of chronic kidney
disease who are initiating dialysis
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-TD (Dialysis subjects with anaemia of CKD)
NCT03400033
|
III
|
A randomised, double-blind, active-controlled, parallel-group,
multi-centre study in hemodialysis participants with anaemia of
chronic kidney disease to evaluate the efficacy, safety and
pharmacokinetics of three-times weekly dosing of daprodustat
compared to recombinant human erythropoietin, following a switch
from recombinant human erythropoietin or its analogs
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-ND (Non-dialysis subjects with anaemia of CKD)
NCT02876835
|
III
|
A randomised, open-label (sponsor-blind), active-controlled,
parallel-group, multi-centre, event driven study in non-dialysis
subjects with anaemia of chronic kidney disease to evaluate the
safety and efficacy of daprodustat compared to darbepoetin
alfa
|
Reported
|
Complete; primary endpoint met
|
|
ASCEND-NHQ (Non-dialysis subjects with anaemia of CKD)
NCT03409107
|
III
|
A 28-week, randomised, double-blind, placebo-controlled,
parallel-group, multi-centre, study in recombinant human
erythropoietin (rhEPO) naïve non-dialysis participants with
anemia of chronic kidney disease to evaluate the efficacy, safety
and effects on quality of life of daprodustat compared to
placebo
|
Reported
|
Complete; primary endpoint met
|
|
Reporting definitions
|
|
Total and Adjusted results
Total
reported results represent the Group’s overall
performance.
GSK
also uses a number of adjusted, non-IFRS, measures to report the
performance of its business. Adjusted results and other non-IFRS
measures may be considered in addition to, but not as a substitute
for or superior to, information presented in accordance with IFRS.
Adjusted results are defined on page 20 and other non-IFRS measures
are defined below.
Free cash flow
Free
cash flow is defined as the net cash inflow/outflow from operating
activities less capital expenditure on property, plant and
equipment and intangible assets, contingent consideration payments,
net finance costs, and dividends paid to non-controlling interests
plus proceeds from the sale of property, plant and equipment and
intangible assets, and dividends received from joint ventures and
associates. It is used by management for planning and reporting
purposes and in discussions with and presentations to investment
analysts and rating agencies. Free cash flow growth is calculated
on a reported basis. A reconciliation of net cash inflow from
operations to free cash flow is set out on page 33.
Free cash flow conversion
Free
cash flow conversion is free cash flow as a percentage of
earnings.
Working capital
Working
capital represents inventory and trade receivables less trade
payables.
CER and AER growth
In
order to illustrate underlying performance, it is the Group’s
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period. CER% represents growth at constant exchange rates. £%
or AER% represents growth at actual exchange rates.
Net debt
Net debt is defined as total borrowings less cash, cash
equivalents, liquid investments, and short-term loans to third
parties that are subject to an insignificant risk of change in
value.
COVID-19 solutions
COVID-19
solutions include the sales of pandemic adjuvant and other COVID-19
solutions including vaccine manufacturing and Xevudy and the associated costs but
does not include reinvestment in R&D. This categorisation is
used by management and we believe is helpful to investors through
providing clarity on the results of the Group by showing the
contribution to growth from COVID-19 solutions.
New GSK
New GSK
refers to the current GSK group excluding the Consumer Healthcare
business that is intended to be (or will have been)
demerged.
General Medicines
General
Medicines are usually prescribed in the primary care or community
settings by general healthcare practitioners. For GSK, this
includes medicines in inhaled respiratory, dermatology, antibiotics
and other diseases.
Specialty Medicines
Specialty
Medicines are typically prescription medicines used to treat
complex or rare chronic conditions. For GSK, this comprises
medicines in infectious diseases, HIV, oncology, immunology and
respiratory.
Organic revenue growth
Organic growth represents revenue growth as determined under IFRS
excluding the impact of acquisitions, divestments and closures of
brands or businesses, revenue attributable to manufacturing service
agreements relating to divestments and the closure of sites or
brands, at CER.
Biopharma
Biopharma
refers to sales in Commercial Operations.
|
|
Brand names and
partner acknowledgements
Brand names appearing in italics throughout this
document are trademarks of GSK or associated companies or used
under licence by the Group.
|
|
Guidance, assumptions and cautionary statements
|
|
2022 guidance
For new GSK we expect sales to grow between 5% to 7% CER and
Adjusted operating profit to grow between 12% to 14% CER as
compared with 2021. This guidance is provided at CER and excludes
the commercial benefit of COVID-19 solutions.
Assumptions related to 2022 guidance
In
outlining the guidance for 2022, the Group has made certain
assumptions about the healthcare sector, the different markets in
which the Group operates and the delivery of revenues and financial
benefits from its current portfolio, pipeline and restructuring
programmes. The Group also assumes that the demerger of our
Consumer Healthcare business will be delivered in July 2022 and
this guidance relates only to new GSK.
The
Group has made planning assumptions for 2022 that healthcare
systems will approach normality as the year progresses, and we
expect sales of Specialty Medicines to grow approximately 10% CER
and sales of General Medicines to show a slight decrease, primarily
reflecting increased genericisation of established Respiratory
medicines. Vaccines sales are expected to grow at a low teens
percentage at CER for the year. However, as noted at the time of
announcing full-year 2021 results, we anticipated
governments’ prioritisation of COVID-19 vaccination
programmes and ongoing measures to contain the pandemic would
result in some continued disruption to adult immunisations. In the
first-quarter 2022 Shingrix
demonstrated strong demand recovery, particularly in the US, as
well as channel inventory build and the benefit of a favourable
comparator to Q1 2021. Despite the potential for short-term
pandemic disruption, we continue to expect strong double-digit
growth and record annual sales for Shingrix in 2022 based on strong demand
in existing markets and continued geographical expansion. Guidance
also includes the future benefit in royalty income from the
settlement and license agreement with Gilead announced on 1
February 2022.
These planning assumptions as well as operating profit guidance and
dividend expectations assume no material interruptions to supply of
the Group’s products, no material mergers, acquisitions or
disposals, no material litigation or investigation costs for the
company (save for those that are already recognised or for which
provisions have been made) and no change in the Group’s
shareholdings in ViiV Healthcare. The assumptions also assume no
material changes in the healthcare environment or unexpected
significant changes in pricing as a result of government or
competitor action. The 2022 guidance factors in all divestments and
product exits announced to date.
The Group’s guidance assumes successful delivery of the
Group’s integration and restructuring plans. It also assumes
that the separation programme to deliver the demerger of the
Consumer Healthcare business is delivered successfully. Material
costs for investment in new product launches and R&D have been
factored into the expectations given. Given the potential
development options in the Group’s pipeline, the outlook may
be affected by additional data-driven R&D investment decisions.
The guidance is given on a constant currency basis.
Assumptions and cautionary statement regarding forward-looking
statements
The
Group’s management believes that the assumptions outlined
above are reasonable, and that the guidance, outlooks, ambitions
and expectations described in this report are achievable based on
those assumptions. However, given the forward-looking nature of
these guidance, outlooks, ambitions and expectations, they are
subject to greater uncertainty, including potential material
impacts if the above assumptions are not realised, and other
material impacts related to foreign exchange fluctuations,
macro-economic activity, the impact of outbreaks, epidemics or
pandemics, such as the COVID-19 pandemic and ongoing challenges and
uncertainties posed by the COVID-19 pandemic for businesses and
governments around the world, changes in legislation, regulation,
government actions or intellectual property protection, product
development and approvals, actions by our competitors, and other
risks inherent to the industries in which we operate.
This
document contains statements that are, or may be deemed to be,
“forward-looking statements”. Forward-looking
statements give the Group’s current expectations or forecasts
of future events. An investor can identify these statements by the
fact that they do not relate strictly to historical or current
facts. They use words such as ‘anticipate’,
‘estimate’, ‘expect’, ‘intend’,
‘will’, ‘project’, ‘plan’,
‘believe’, ‘target’ and other words and
terms of similar meaning in connection with any discussion of
future operating or financial performance. In particular, these
include statements relating to future actions, prospective products
or product approvals, future performance or results of current and
anticipated products, sales efforts, expenses, the outcome of
contingencies such as legal proceedings, dividend payments and
financial results. Other than in accordance with its legal or
regulatory obligations (including under the Market Abuse
Regulation, the UK Listing Rules and the Disclosure and
Transparency Rules of the Financial Conduct Authority), the Group
undertakes no obligation to update any forward-looking statements,
whether as a result of new information, future events or otherwise.
The reader should, however, consult any additional disclosures that
the Group may make in any documents which it publishes and/or files
with the SEC. All readers, wherever located, should take note of
these disclosures. Accordingly, no assurance can be given that any
particular expectation will be met and investors are cautioned not
to place undue reliance on the forward-looking
statements.
All
outlooks, ambitions considerations should be read together with;
for Haleon the section “Assumptions and cautionary statement
and regarding forward-looking statements” on page 163 of the
Haleon Capital Markets Day all presentation slides dated 28
February 2022, and for GSK pages 5-7 of the Stock Exchange
announcement relating to an update to investors dated 23 June 2021
and the Guidance, assumptions and cautionary statements of our Q2
2021 earnings release.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group’s control or precise estimate. The Group cautions
investors that a number of important factors, including those in
this document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under Item
3.D ‘Risk Factors’ in the Group’s Annual Report
on Form 20-F for 2021 and any impacts of the COVID-19 pandemic. Any
forward looking statements made by or on behalf of the Group speak
only as of the date they are made and are based upon the knowledge
and information available to the Directors on the date of this
report.
|
|
Independent review report to GlaxoSmithKline plc
|
|
We have
been engaged by GlaxoSmithKline plc (“the Company”) to
review the condensed financial information in the Results
Announcement of the Company for the three months ended 31 March
2022.
|
|
What we have reviewed
|
|
|
The
condensed financial information comprises:
|
|
|
●
|
the
income statement and statement of comprehensive income for the
three month period ended 31 March 2022 on pages 22 to
23;
|
|
●
|
the
balance sheet as at 31 March 2022 on page 26;
|
|
●
|
the
statement of changes in equity for the three month period then
ended on page 27;
|
|
●
|
the
cash flow statement for the three month period then ended on page
28 and;
|
|
●
|
the
accounting policies and basis of preparation and the explanatory
notes to the condensed financial information on pages 24 to 25 and
29 to 33 that have been prepared applying consistent accounting
policies to those applied by the Group in the Annual Report 2021,
which was prepared in accordance with International Financial
Reporting Standards (“IFRS”) as adopted by the United
Kingdom.
|
|
|
|
|
We have
read the other information contained in the Results Announcement,
including the non-IFRS measures contained on pages 24 to 25 and 29
to 33, and considered whether it contains any apparent
misstatements or material inconsistencies with the information in
the condensed set of financial statements.
This
report is made solely to the Company in accordance with
International Standard on Review Engagements (UK and Ireland) 2410
“Review of Interim Financial Information Performed by the
Independent Auditor of the Entity” issued by the Auditing
Practices Board. Our work has been undertaken so that we might
state to the Company those matters we are required to state to it
in an independent review report and for no other purpose. To the
fullest extent permitted by law, we do not accept or assume
responsibility to anyone other than the Company, for our review
work, for this report, or for the conclusions we have
formed.
Directors’ responsibilities
The
Results Announcement of GlaxoSmithKline plc, including the
condensed financial information, is the responsibility of, and has
been approved by, the directors. The directors are responsible for
preparing the Results Announcement by applying consistent
accounting policies to those applied by the Group in the Annual
Report 2021, which are prepared in accordance with IFRS as adopted
by the United Kingdom.
Our responsibility
Our
responsibility is to express to the Company a conclusion on the
interim financial information in the Results Announcement based on
our review.
Scope of review
We
conducted our review in accordance with International Standard on
Review Engagements (UK and Ireland) 2410 “Review of Interim
Financial Information Performed by the Independent Auditor of the
Entity” issued by the Auditing Practices Board for use in the
United Kingdom. A review of interim financial information consists
of making inquiries, primarily of persons responsible for financial
and accounting matters, and applying analytical and other review
procedures. A review is substantially less in scope than an audit
conducted in accordance with International Standards on Auditing
(UK) and consequently does not enable us to obtain assurance that
we would become aware of all significant matters that might be
identified in an audit. Accordingly, we do not express an audit
opinion.
Conclusion
Based
on our review, nothing has come to our attention that causes us to
believe that the condensed financial information in the Results
Announcement for the three months ended 31 March 2022 are not
prepared, in all material respects in accounting policies set out
in the accounting policies and basis of preparation section on page
31.
Deloitte LLP
Statutory
Auditor
London,
United Kingdom
27
April 2022
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: April
27, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|